TY - JOUR
AU - Camici, P G
AB - Summary Far from being merely a passive cholesterol accumulation within the arterial wall, the development of atherosclerosis is currently known to imply both inflammation and immune effector mechanisms. Adaptive immunity has been implicated in the process of disease initiation and progression interwined with traditional cardiovascular risk factors. Although the body of knowledge regarding the correlation between atherosclerosis and immunity in humans is growing rapidly, a relevant proportion of it derives from studies carried out in animal models of cardiovascular disease (CVD). However, while the mouse is a well-suited model, the results obtained therein are not fully transferrable to the human setting due to intrinsic genomic and environmental differences. In the present review, we will discuss mainly human findings, obtained either by examination of post-mortem and surgical atherosclerotic material or through the analysis of the immunological profile of peripheral blood cells. In particular, we will discuss the findings supporting a pro-atherogenic role of T cell subsets, such as effector memory T cells or the potential protective function of regulatory T cells. Recent studies suggest that traditional T cell-driven B2 cell responses appear to be atherogenic, while innate B1 cells appear to exert a protective action through the secretion of naturally occurring antibodies. The insights into the immune pathogenesis of atherosclerosis can provide new targets in the quest for novel therapeutic targets to abate CVD morbidity and mortality. atherosclerosis, B cells, coronary artery disease, effector memory T cells, T cells Introduction Cardiovascular disease (CVD) is currently the most common cause of death globally, accouting for nearly one-third of deceases worldwide [1]. While many diseases can affect the cardiovascular (CV) system, atherosclerosis is by far the most common, and atherosclerosis-related conditions, including acute myocardial infarction (AMI) and stroke, dominate death and disability statistics throughout the world [2]. Atherosclerosis is a chronic disease that affects medium- and large-sized arteries. By causing severe stenosis or thrombosis in arteries it leads to regional ischaemic damage, which may result in life-threatening conditions [3]. According to the prevailing view, cholesterol accumulation in the vessel wall, in particular the fraction assembled in low-density lipoproteins (LDL), has a central role in atherogenesis. The association between cholesterol and human atherosclerosis has been proved by epidemiological studies [4,5], and further research into cholesterol metabolism has led to the implementation of preventive programmes that avert thousands of deaths worldwide [6]. Notably, the introduction of hydroxy-methyl glutaryl CoA (HMG-CoA) reductase inhibitors, i.e. statins, a class of cholesterol-lowering drugs, decreased the incidence of major CV events, including stroke and AMI, by approximately one-third [6]. Similar results have been obtained with campaigns aimed to reduce systemic hypertension and cigarette consumption [7,8]. Despite the outstanding results obtained by such preventive programmes, a substantial residual risk needs to be addressed to further abate CVD incidence and related mortality. New insights in pathogenic elements of atherosclerosis beyond lipid profile have assumed major interest in the quest for novel and effective therapeutic interventions to treat atherosclerosis. Population-based observations are useful for this purpose: using genomewide association studies, for example, a locus on chromosome 9p21 has been identified repeatedly as one of the main determinants of complex CVD, and risk-associated polymorphisms seem to be responsible for up to 21% of attributable risk of AMI independently of well-established CV risk factors (CVRFs) [9,10]. Most interestingly, compelling evidence building continuously over recent years links inflammation and adaptive immune response to atherogenesis [11]. Immune mechanisms also appear to underlie the pathogenesis of traditional CVRFs, including hypertension, diabetes mellitus (DM) and metabolic syndrome [12,13], and to be dysregulated on a genetic basis [i.e. interleukin (IL)-6 receptor variant] [14], at least in some individuals. Although the body of knowledge regarding the correlation between atherosclerosis and immunity is growing at an untoward speed, a relevant proportion of it derives from studies carried out in animal models of CVD, the mouse being the most widely studied due to its low cost of maintenance, fast reproduction rate and easy genetic manipulation [15]. While experimental research has provided key mechanistic insights, it remains unclear whether the identified pathways may contribute to human atherosclerosis, due mainly to the intrinsic genomic and environmental differences between humans and animal models [16]. The present review addresses established knowledge and evidence gaps in the aetiology of atherosclerosis with particular focus on human findings, which can be attained through a number of techniques summarized in Table 1, most notably including pathological examination of post mortem or surgical atherosclerosis samples or through the analysis of the immunological profile in peripheral blood, and we will try to underline their clinical significance and potential therapeutic implications, alongside some key pathogenic evidence derived from experimental studies. Table 1 Summary of the main techniques and biological materials employed in the study of the relationship between adaptive immune response and atherosclerosis in humans Technique . Material . Attainable results . Classical histology Surgical or post mortem pathological sample of atherosclerotic lesions Purely morphological analysis of the plaque and its cellular components Immunohistochemistry and immunofluorescence Surgical or post mortem pathological sample of atherosclerotic lesions Identification-specific cellular subtypes or presence of proteins by exploiting antibody–antigen reaction Real-time polymerase chain reaction (RT–PCR) Peripheral blood mononuclear cells (PBMC)-derived cDNA Quantification of mRNA of proteins relevant to adaptive immunity, generally cytokines, as an indirect measure of their expression by circulating immune cells Enzyme-linked immunosorbent assay (ELISA) Plasma Direct quantification of relevant soluble proteins, generally cytokines Flow cytometry Whole blood or PBMC Characterization and quantification of immune cells subpopulations through the identification of surface markers Technique . Material . Attainable results . Classical histology Surgical or post mortem pathological sample of atherosclerotic lesions Purely morphological analysis of the plaque and its cellular components Immunohistochemistry and immunofluorescence Surgical or post mortem pathological sample of atherosclerotic lesions Identification-specific cellular subtypes or presence of proteins by exploiting antibody–antigen reaction Real-time polymerase chain reaction (RT–PCR) Peripheral blood mononuclear cells (PBMC)-derived cDNA Quantification of mRNA of proteins relevant to adaptive immunity, generally cytokines, as an indirect measure of their expression by circulating immune cells Enzyme-linked immunosorbent assay (ELISA) Plasma Direct quantification of relevant soluble proteins, generally cytokines Flow cytometry Whole blood or PBMC Characterization and quantification of immune cells subpopulations through the identification of surface markers Open in new tab Table 1 Summary of the main techniques and biological materials employed in the study of the relationship between adaptive immune response and atherosclerosis in humans Technique . Material . Attainable results . Classical histology Surgical or post mortem pathological sample of atherosclerotic lesions Purely morphological analysis of the plaque and its cellular components Immunohistochemistry and immunofluorescence Surgical or post mortem pathological sample of atherosclerotic lesions Identification-specific cellular subtypes or presence of proteins by exploiting antibody–antigen reaction Real-time polymerase chain reaction (RT–PCR) Peripheral blood mononuclear cells (PBMC)-derived cDNA Quantification of mRNA of proteins relevant to adaptive immunity, generally cytokines, as an indirect measure of their expression by circulating immune cells Enzyme-linked immunosorbent assay (ELISA) Plasma Direct quantification of relevant soluble proteins, generally cytokines Flow cytometry Whole blood or PBMC Characterization and quantification of immune cells subpopulations through the identification of surface markers Technique . Material . Attainable results . Classical histology Surgical or post mortem pathological sample of atherosclerotic lesions Purely morphological analysis of the plaque and its cellular components Immunohistochemistry and immunofluorescence Surgical or post mortem pathological sample of atherosclerotic lesions Identification-specific cellular subtypes or presence of proteins by exploiting antibody–antigen reaction Real-time polymerase chain reaction (RT–PCR) Peripheral blood mononuclear cells (PBMC)-derived cDNA Quantification of mRNA of proteins relevant to adaptive immunity, generally cytokines, as an indirect measure of their expression by circulating immune cells Enzyme-linked immunosorbent assay (ELISA) Plasma Direct quantification of relevant soluble proteins, generally cytokines Flow cytometry Whole blood or PBMC Characterization and quantification of immune cells subpopulations through the identification of surface markers Open in new tab Innate immunity recruits adaptive response in atherosclerosis The recognition of disease-specific antigens by germline-encoded pattern recognition receptors initiates a local inflammatory response against pathogens or components of the host itself. Inflammatory responses are usually adaptive, either killing the eliciting pathogen or contributing to homeostasis by stimulating the removal of damaged tissue and dead cells by phagocytes. Conversely, inflammation may be pathogenic by fuelling local tissue damage itself: such a maladaptive inflammatory process appears to be a relevant driving process in atherosclerosis initiation and progression [17]. The antigens involved in inflammation initiation in atherosclerosis are only recently beginning to be elucidated. Infectious agents may contribute to provoking a response, but a primary role is currently considered unlikely [18–20], although epidemiological studies provided evidence of an association between recent systemic respiratory and urinary tract infections and the first AMI or stroke based on 39 546 first CV events [21]. By contrast, influenza, tetanus and pneumococcal vaccinations do not produce a detectable increase in the risk of vascular events [21]. Other potential antigens, such as heat shock proteins (HSPs) [22] and cholesterol crystals [23], have been implied, but as both require pre-existing tissue damage they are not likely to initiate the primary inflammatory cascade. At present, however, much evidence suggests that potential major antigens involved in atherosclerosis consist of neoepitopes generated by either enzymatic or non-enzymatic oxidation reactions that occur when oxidized LDL (oxLDL) form in the vessel wall or when cells undergo apoptotic death [24]. The resulting oxidation-specific epitopes (OSEs) constitute a signature of oxidative damage and are thus the target of a common set of pattern recognition receptors, which renders them proinflammatory and immunogenic [24]. Furthermore, other potential antigens derived by apoptotic cells in the plaques can further promote the progression of the atherosclerotic plaque, and defects in apoptotic cell clearance can sustain atherogenesis [25]. For instance, the CDKN2B gene, encoding the cyclin-dependent kinase inhibitor 2B that has reduced expression in human carriers of the 9p21 risk allele, has been demonstrated to regulate the clearance of apoptotic debris [26,27]. Its loss of function can increase the size of plaque and its lipid core in mice, decreasing the successful engulfment process (efferocytosis) mediated by phagocytic cells [27], thus leading to an inflammatory danger response by apoptotic cells evading clearance [28]. Importantly, the innate immune response is accompanied by secretion of chemokines and cytokines as well as antigen presentation, which together co-operate to initiate the definitive adaptive immune response. Dendritic cells (DCs) in particular are the specific cells in charge of initiating of antigen-specific immunity and tolerance [29]. DCs drive the maturation and polarization of naive T cells through surface exposure of antigenic peptides in the context of a major histocompatibility complex (MHC) class II molecule, alongside the exposure of appropriate membrane-bound signalling molecules and the secretion of cytokines [29]. Mature DCs, i.e. those that have undergone stimulation of their pattern recognition receptors, induce T cell activation and polarization by providing appropriate co-stimulation [30]. Conversely, immature DCs as well as DCs receiving strong anti-inflammatory signals, i.e. through the action of cytokines such as transforming growth factor (TGF)-β or IL-10, do not provide co-stimulation and thus induce T cell anergy or death, or skew the response towards a regulatory phenotype [30]. In the mouse, a cellular immune response to apolipoprotein (Apo) B100 of native LDL has been identified as an important player in atherosclerosis [31]. Selective MHC-II deficiency on DC in LDL receptor null (LDLR−/−) chimeric mice showed reduced plaque formation, further supporting a pro-atherogenic role for DCs and identifying a critical role for MHC-II-restricted antigen presentation by DCs in driving pro-atherogenic T cell immunity [32]. In humans, patients with symptomatic coronary artery disease (CAD) showed increased lesional levels of so-called homeostatic chemokines (CCL19 and CCL21) that, together with their receptor CCR7, play a pivotal role in lymphocyte trafficking by promoting infiltration of T cells and encounter DCs in lymphoid tissue [33]. Furthermore, DCs are found in the intima and adventitia of normal human arteries, and their number was shown to increase with the formation and the progression of atherosclerotic lesions [34,35], supporting the hypothesis that a stronger activation of adaptive immune response parallels the progression of atherosclerotic disease. T cell response in atherosclerosis The hypothesis that adaptive immunity operates in human atherosclerosis has spread from studies carried out in the 1980s, demonstrating widespread expression of the MHC-II molecule human leucocyte antigen D-related (HLA-DR) in human atheroma [36], alongside a large number of CD3+ T cells [37]. Most T cells within human atherosclerotic plaques display an effector memory phenotype, a large proportion of which show signs of activation, and approximately two-thirds of them are CD4+ T helper cells (Th) bearing the αβ T cell receptor (TCR) [38]. CD8+ cytotoxic T cells are also abundant in human atherosclerotic plaques. T cells are among the first cells to be recruited within the atheroma, and they are enriched in unstable plaques, i.e. atherosclerotic plaques prone to rupture and subsequently causing thrombosis, embolism and acute cardiovascular manifestations [39,40]. Beyond macrophage infiltration, atherosclerotic lesions of patients suffering acute coronary syndromes (ACS) are infiltrated with oligoclonal T cells, demonstrating an ongoing, antigen-driven immune response [41], and specific activated T cell subsets have been recognized with monoclonal TCR, such as HLA-DR+ and CD28null T cells [42,43]. As underlined previously, a key unresolved question is the identification of relevant antigens recognized by these cells. While the inflammatory milieu of the plaque may recruit an unspecific heterogeneous population of polyclonal cells, most T cells isolated and cloned from human plaques respond to oxLDL or other antigens under current investigation, i.e. antigenic determinant of the bacterial wall [44], in a HLA-DR-restricted manner [45]. Furthermore, oral viridans streptococci DNA was measured in 78% of thrombi of patients with AMI, underscoring the fact that activation of inflammatory pathways in ACS is not confined to coronary lesions but is also contained in the thrombus [46]. Many such antigens can be found systemically. Thus, effector T cell responses are most probably initiated in secondary lymphoid organs such as lymph nodes and the spleen, and activated T cells are thought to recirculate to atherosclerotic lesions where putative antigens are present. The finding that patients with CAD have an increase of chemokine receptors involved in T cell plaque recruitment, i.e. CCR5 and CXCR3, on the CD4+ T cell surface supports this hypothesis [47]. Of note, inhibition of chemokine receptors that are involved in the recruitment of circulating T cells into human plaque such as CCR5 and CXCR3 [48,49] attenuates atherosclerotic lesion formation in animal models [50,51]. Therefore, atherogenic T cell responses can be considered systemic, providing the rationale for the study of T cells both within the plaque and systemically, through the analysis of T cells profile in peripheral blood (Fig. 1). Table 2 summarizes the main findings concerned with T cell responses in human atherosclerosis. Fig. 1 Open in new tabDownload slide T cells and atherosclerotic plaque development. Within secondary and tertiary lymphoid organs, activated dendritic cells polarize naive CD4+T helper (Th) cells in different types of effector T cell through antigen presentation alongside secretion of cytokines and co-stimulation. Th1, Th2 and Th17 subsets are categorized by the cytokine they release. Tolerogenic dendritic cells prime naive CD4+ cells toward a regulatory phenotype (regulatory T cells: Tregs). The ontogeny of CD28nullCD4+ is currently a matter of active investigation. Upon acquisition of an effector memory phenotype, characterized by the expression of CD45RO, human leucocyte antigen D-related (HLA-DR) and chemokines receptor CCR5, activated T cells recirculate in peripheral blood. The secretion of cytokines and chemokines from the plaque drives their homing to the atherosclerotic lesion, where they exert diverse actions. Th1 cells promote endothelial disfunction, lipid accumulation in macrophages with subsequent foam cell formation, and cell death through the secretion of their master cytokine interferon (IFN)-γ, exerting a pro-atherogenic effect. The role of Th2 has not yet been elucidated, but appears to be atheroprotective, due possibly to inhibition of Th1 cells. The role of Th17 is currently under intense investigation. Tregs appear to be atheroprotective through the induction of tolerance, the inhibition of atherogenic T cell subsets and suppression of inflammation. CD28nullCD4+ exert a pro-atherogenic action through the secretion of proinflammatory cytokines and cell-mediated cytotoxicity. They were shown to resist Treg inhibition. Human atherosclerotic plaques are also infiltated with CD8+ cytotoxic T cells, which exert an atherogenic effect through induction of cell death. SMC = smooth muscle cells; IL-4: interleukin 4; IL17: interleukin 17; FoxP3: forkhead box protein 3; OX40: CD 131. Fig. 1 Open in new tabDownload slide T cells and atherosclerotic plaque development. Within secondary and tertiary lymphoid organs, activated dendritic cells polarize naive CD4+T helper (Th) cells in different types of effector T cell through antigen presentation alongside secretion of cytokines and co-stimulation. Th1, Th2 and Th17 subsets are categorized by the cytokine they release. Tolerogenic dendritic cells prime naive CD4+ cells toward a regulatory phenotype (regulatory T cells: Tregs). The ontogeny of CD28nullCD4+ is currently a matter of active investigation. Upon acquisition of an effector memory phenotype, characterized by the expression of CD45RO, human leucocyte antigen D-related (HLA-DR) and chemokines receptor CCR5, activated T cells recirculate in peripheral blood. The secretion of cytokines and chemokines from the plaque drives their homing to the atherosclerotic lesion, where they exert diverse actions. Th1 cells promote endothelial disfunction, lipid accumulation in macrophages with subsequent foam cell formation, and cell death through the secretion of their master cytokine interferon (IFN)-γ, exerting a pro-atherogenic effect. The role of Th2 has not yet been elucidated, but appears to be atheroprotective, due possibly to inhibition of Th1 cells. The role of Th17 is currently under intense investigation. Tregs appear to be atheroprotective through the induction of tolerance, the inhibition of atherogenic T cell subsets and suppression of inflammation. CD28nullCD4+ exert a pro-atherogenic action through the secretion of proinflammatory cytokines and cell-mediated cytotoxicity. They were shown to resist Treg inhibition. Human atherosclerotic plaques are also infiltated with CD8+ cytotoxic T cells, which exert an atherogenic effect through induction of cell death. SMC = smooth muscle cells; IL-4: interleukin 4; IL17: interleukin 17; FoxP3: forkhead box protein 3; OX40: CD 131. Table 2 Summary of main findings concerned with T cell-mediated immune response in human atherosclerosis Intraplaque T cells . Subtype . Finding . Number of patients . Sample . Reference . Th1 Most abundant subtype, oligoclonal expansion correlates with lesion progression and inflammation 10 (9 carotid arteries, 1 femoral artery) Carotid artery and femoral artery endarterectomies Frostegard, 1999 [52] Th17 Controversial, local production of IL-17A, a master cytokine, correlates with inflammation and instabilization 79 Carotid endarterectomy Erbel, 2011 [53] CD4+CD28null Oligoclonal expansion in plaque inflammation and instability 1 Coronary artery post mortem specimen Liuzzo, 2000 [43] Tregs Reduced in early stage lesions 45 Aorta, carotid artery and femoral artery specimens De Boer, 2007 [54] Increased in unstable, symptomatic lesions 57 Carotid endarterectomy Patel, 2011 [55] Increased with TCR restriction in thrombus aspirates from ACS patients 16 Thrombus aspirates Klingenberg, 2014 [56] NK T cells Likely to be pro-atherogenic 7 Carotid endarterectomy Bobryshev, 2005 [57] Intraplaque T cells . Subtype . Finding . Number of patients . Sample . Reference . Th1 Most abundant subtype, oligoclonal expansion correlates with lesion progression and inflammation 10 (9 carotid arteries, 1 femoral artery) Carotid artery and femoral artery endarterectomies Frostegard, 1999 [52] Th17 Controversial, local production of IL-17A, a master cytokine, correlates with inflammation and instabilization 79 Carotid endarterectomy Erbel, 2011 [53] CD4+CD28null Oligoclonal expansion in plaque inflammation and instability 1 Coronary artery post mortem specimen Liuzzo, 2000 [43] Tregs Reduced in early stage lesions 45 Aorta, carotid artery and femoral artery specimens De Boer, 2007 [54] Increased in unstable, symptomatic lesions 57 Carotid endarterectomy Patel, 2011 [55] Increased with TCR restriction in thrombus aspirates from ACS patients 16 Thrombus aspirates Klingenberg, 2014 [56] NK T cells Likely to be pro-atherogenic 7 Carotid endarterectomy Bobryshev, 2005 [57] Circulating T cells . Subtype . Markers . Investigated condition . Finding . Number of patients . References . Th1 CD3+IFN-γ+ ACS and stable CAD Higher activation in ACS compared with stable CAD. Higher activation in ACS and stable CAD compared to controls 28 ACS; 18 stable CAD; 16 controls Methe, 2005 [58] CD3+CD56−CD4+IFN-γ+ ACS and stroke Inverse correlation with ACS and stroke risk evaluated prospectively 700 Engelbertsen, 2013 [59] CD4+CCR7− Stable and unstable angina Increased proportion in stable and unstable angina when compared to controls 40 stable angina; 40 unstable angina; 20 controls Damas, 2007 [33] HLA-DR+CD3+CD4+CD45RA−CD45RO+CCR7− Carotid IMT and CAD Correlation with IMT and association with CAD and cardiovascular risk factor 183 carotid group; 130 CAD group Ammirati, 2012 [60] CD3+HLA-DR+ Unstable and stable angina Increased in unstable angina compared to stable angina and controls 23 unstable angina; 13 chronic stable angina; 6 controls Caligiuri, 2000 [42] CD3+HLA-DR+ Unstable and stable angina Increased in unstable angina compared to stable angina and controls 29 stable angina; 36 stable angina; 30 controls Neri-Serneri, 1997 [61] CD4+CD28null CD4+CD28null Unstable angina and stable CAD Increased in unstable angina compared to stable CAD and controls 25 unstable angina; 25 stable angina; 21 hospitalized controls; 20 healthy controls Liuzzo, 1999 [62] CD4+CD28null ACS, stable angina and CVRF without CAD No differences among groups and with controls 20 ACS; 30 stable angina; 22 CVRF no CAD; 16 controls Teo, 2013 [63] TCR zeta-dim TCR zeta-dim ACS and chronic stable angina Increased proportion in ACS patients compared to chronic stable angina. Increase was higher in patients with higher C-reactive protein. Subsets enriched with TCR zeta-dim where CD8+, NK and CD4+CD28null 66 ACS; 32 stable angina Ammirati, 2008 [64] Th17 CD4+IL-17A+ ACS and Stable CAD Increased in AC with respect to stable CAD and controls 43 (ACS); 22 (stable CAD); 20 (controls) Cheng, 2008 [65] CD4+IL-17 + ACS and stable CAD No association 44 (ACS); 20 (stable CAD); 24 (controls) Zhao, 2011 [66] Th17/Th1 CD4+IL-17+IFN-γ+ ACS and stable CAD Increased in ACS 44 (ACS); 20 (stable CAD); 24 (controls) Zhao, 2011 [66] Th2 CD3+CD56−CD4+IL-4 + Carotid mean IMT and area, stroke and ACS Inverse correlation with carotid mean IMT and area, and with the risk of stroke and ACS evaluated prospectively 700 Engelbertsen, 2013 [59] ACS recurrence Elevated in patients suffering from ACS recurrence during 2-year follow-up 120 Liuzzo, 2007 [67] Tregs CD4+CD25+FoxP3+ ACS and stable CAD Reduced number in ACS, no correlation with stable CAD 40 ACS; 18 stable CAD; 20 controls Han, 2005 [68] CD4+CD25high ACS and stable CAD Reduced number and functionally compromised in ACS, no correlation for stable CAD 40 ACS; 28 stable CAD; 28 controls Mor, 2006 [69] CD4+CD25hiCD127lo Carotid IMT, stable CAD, ACS (ST-elevation and non-ST-elevation AMI) No correlation with IMT or IMT progression. No correlation in stable CAD. Reduced in non-ST elevation AMI, increased in ST-elevation AMI 113 carotid group; 200 coronary group (75 controls, 36 stable angina, 50 non-ST elevation AMI, 39 ST-elevation AMI) Ammirati, 2010 [70] CD3+CD4+CD25hiCD127loCCR5+ Carotid IMT, stable CAD, ACS (ST-elevation and non-ST-elevation AMI) No correlation with either CAD or carotid IMT 113 carotid group; 150 coronary group (25 controls, 36 stable angina, 50 Non-ST elevation AMI, 39 ST-elevation AMI) Ammirati, 2010 [70] T effector memory CD3+CD4+CD45RA−CD45RO+CCR7− Carotid IMT and CAD Correlation with IMT and association with CAD and cardiovascular risk factor 183 carotid group; 130 CAD group Ammirati, 2012 [47] CD4+CD45RA-CD45RO+ Carotid IMT and coronary arteries calcifications Positive correlation with carotid IMT and coronary arteries calcifications 912 Olson, 2013 [71] CD4+CD45RO+ Carotid IMT Positive correlation with carotid IMT 557 Tanigawa, 2003 [72] Circulating T cells . Subtype . Markers . Investigated condition . Finding . Number of patients . References . Th1 CD3+IFN-γ+ ACS and stable CAD Higher activation in ACS compared with stable CAD. Higher activation in ACS and stable CAD compared to controls 28 ACS; 18 stable CAD; 16 controls Methe, 2005 [58] CD3+CD56−CD4+IFN-γ+ ACS and stroke Inverse correlation with ACS and stroke risk evaluated prospectively 700 Engelbertsen, 2013 [59] CD4+CCR7− Stable and unstable angina Increased proportion in stable and unstable angina when compared to controls 40 stable angina; 40 unstable angina; 20 controls Damas, 2007 [33] HLA-DR+CD3+CD4+CD45RA−CD45RO+CCR7− Carotid IMT and CAD Correlation with IMT and association with CAD and cardiovascular risk factor 183 carotid group; 130 CAD group Ammirati, 2012 [60] CD3+HLA-DR+ Unstable and stable angina Increased in unstable angina compared to stable angina and controls 23 unstable angina; 13 chronic stable angina; 6 controls Caligiuri, 2000 [42] CD3+HLA-DR+ Unstable and stable angina Increased in unstable angina compared to stable angina and controls 29 stable angina; 36 stable angina; 30 controls Neri-Serneri, 1997 [61] CD4+CD28null CD4+CD28null Unstable angina and stable CAD Increased in unstable angina compared to stable CAD and controls 25 unstable angina; 25 stable angina; 21 hospitalized controls; 20 healthy controls Liuzzo, 1999 [62] CD4+CD28null ACS, stable angina and CVRF without CAD No differences among groups and with controls 20 ACS; 30 stable angina; 22 CVRF no CAD; 16 controls Teo, 2013 [63] TCR zeta-dim TCR zeta-dim ACS and chronic stable angina Increased proportion in ACS patients compared to chronic stable angina. Increase was higher in patients with higher C-reactive protein. Subsets enriched with TCR zeta-dim where CD8+, NK and CD4+CD28null 66 ACS; 32 stable angina Ammirati, 2008 [64] Th17 CD4+IL-17A+ ACS and Stable CAD Increased in AC with respect to stable CAD and controls 43 (ACS); 22 (stable CAD); 20 (controls) Cheng, 2008 [65] CD4+IL-17 + ACS and stable CAD No association 44 (ACS); 20 (stable CAD); 24 (controls) Zhao, 2011 [66] Th17/Th1 CD4+IL-17+IFN-γ+ ACS and stable CAD Increased in ACS 44 (ACS); 20 (stable CAD); 24 (controls) Zhao, 2011 [66] Th2 CD3+CD56−CD4+IL-4 + Carotid mean IMT and area, stroke and ACS Inverse correlation with carotid mean IMT and area, and with the risk of stroke and ACS evaluated prospectively 700 Engelbertsen, 2013 [59] ACS recurrence Elevated in patients suffering from ACS recurrence during 2-year follow-up 120 Liuzzo, 2007 [67] Tregs CD4+CD25+FoxP3+ ACS and stable CAD Reduced number in ACS, no correlation with stable CAD 40 ACS; 18 stable CAD; 20 controls Han, 2005 [68] CD4+CD25high ACS and stable CAD Reduced number and functionally compromised in ACS, no correlation for stable CAD 40 ACS; 28 stable CAD; 28 controls Mor, 2006 [69] CD4+CD25hiCD127lo Carotid IMT, stable CAD, ACS (ST-elevation and non-ST-elevation AMI) No correlation with IMT or IMT progression. No correlation in stable CAD. Reduced in non-ST elevation AMI, increased in ST-elevation AMI 113 carotid group; 200 coronary group (75 controls, 36 stable angina, 50 non-ST elevation AMI, 39 ST-elevation AMI) Ammirati, 2010 [70] CD3+CD4+CD25hiCD127loCCR5+ Carotid IMT, stable CAD, ACS (ST-elevation and non-ST-elevation AMI) No correlation with either CAD or carotid IMT 113 carotid group; 150 coronary group (25 controls, 36 stable angina, 50 Non-ST elevation AMI, 39 ST-elevation AMI) Ammirati, 2010 [70] T effector memory CD3+CD4+CD45RA−CD45RO+CCR7− Carotid IMT and CAD Correlation with IMT and association with CAD and cardiovascular risk factor 183 carotid group; 130 CAD group Ammirati, 2012 [47] CD4+CD45RA-CD45RO+ Carotid IMT and coronary arteries calcifications Positive correlation with carotid IMT and coronary arteries calcifications 912 Olson, 2013 [71] CD4+CD45RO+ Carotid IMT Positive correlation with carotid IMT 557 Tanigawa, 2003 [72] IFN = interferon; IL = interleukin; Th = T helper; NK = natural killer; TCR = T cell receptor; ACS = acute coronary syndromes; CAD = coronary artery disease; HLA-DR = human leucocyte antigen D-related; IMT = intima medial thickness; CVRF = cardiovascular risk factor; FoxP3 = forkhead box P3; AMI = acute myocardial infarction. Open in new tab Table 2 Summary of main findings concerned with T cell-mediated immune response in human atherosclerosis Intraplaque T cells . Subtype . Finding . Number of patients . Sample . Reference . Th1 Most abundant subtype, oligoclonal expansion correlates with lesion progression and inflammation 10 (9 carotid arteries, 1 femoral artery) Carotid artery and femoral artery endarterectomies Frostegard, 1999 [52] Th17 Controversial, local production of IL-17A, a master cytokine, correlates with inflammation and instabilization 79 Carotid endarterectomy Erbel, 2011 [53] CD4+CD28null Oligoclonal expansion in plaque inflammation and instability 1 Coronary artery post mortem specimen Liuzzo, 2000 [43] Tregs Reduced in early stage lesions 45 Aorta, carotid artery and femoral artery specimens De Boer, 2007 [54] Increased in unstable, symptomatic lesions 57 Carotid endarterectomy Patel, 2011 [55] Increased with TCR restriction in thrombus aspirates from ACS patients 16 Thrombus aspirates Klingenberg, 2014 [56] NK T cells Likely to be pro-atherogenic 7 Carotid endarterectomy Bobryshev, 2005 [57] Intraplaque T cells . Subtype . Finding . Number of patients . Sample . Reference . Th1 Most abundant subtype, oligoclonal expansion correlates with lesion progression and inflammation 10 (9 carotid arteries, 1 femoral artery) Carotid artery and femoral artery endarterectomies Frostegard, 1999 [52] Th17 Controversial, local production of IL-17A, a master cytokine, correlates with inflammation and instabilization 79 Carotid endarterectomy Erbel, 2011 [53] CD4+CD28null Oligoclonal expansion in plaque inflammation and instability 1 Coronary artery post mortem specimen Liuzzo, 2000 [43] Tregs Reduced in early stage lesions 45 Aorta, carotid artery and femoral artery specimens De Boer, 2007 [54] Increased in unstable, symptomatic lesions 57 Carotid endarterectomy Patel, 2011 [55] Increased with TCR restriction in thrombus aspirates from ACS patients 16 Thrombus aspirates Klingenberg, 2014 [56] NK T cells Likely to be pro-atherogenic 7 Carotid endarterectomy Bobryshev, 2005 [57] Circulating T cells . Subtype . Markers . Investigated condition . Finding . Number of patients . References . Th1 CD3+IFN-γ+ ACS and stable CAD Higher activation in ACS compared with stable CAD. Higher activation in ACS and stable CAD compared to controls 28 ACS; 18 stable CAD; 16 controls Methe, 2005 [58] CD3+CD56−CD4+IFN-γ+ ACS and stroke Inverse correlation with ACS and stroke risk evaluated prospectively 700 Engelbertsen, 2013 [59] CD4+CCR7− Stable and unstable angina Increased proportion in stable and unstable angina when compared to controls 40 stable angina; 40 unstable angina; 20 controls Damas, 2007 [33] HLA-DR+CD3+CD4+CD45RA−CD45RO+CCR7− Carotid IMT and CAD Correlation with IMT and association with CAD and cardiovascular risk factor 183 carotid group; 130 CAD group Ammirati, 2012 [60] CD3+HLA-DR+ Unstable and stable angina Increased in unstable angina compared to stable angina and controls 23 unstable angina; 13 chronic stable angina; 6 controls Caligiuri, 2000 [42] CD3+HLA-DR+ Unstable and stable angina Increased in unstable angina compared to stable angina and controls 29 stable angina; 36 stable angina; 30 controls Neri-Serneri, 1997 [61] CD4+CD28null CD4+CD28null Unstable angina and stable CAD Increased in unstable angina compared to stable CAD and controls 25 unstable angina; 25 stable angina; 21 hospitalized controls; 20 healthy controls Liuzzo, 1999 [62] CD4+CD28null ACS, stable angina and CVRF without CAD No differences among groups and with controls 20 ACS; 30 stable angina; 22 CVRF no CAD; 16 controls Teo, 2013 [63] TCR zeta-dim TCR zeta-dim ACS and chronic stable angina Increased proportion in ACS patients compared to chronic stable angina. Increase was higher in patients with higher C-reactive protein. Subsets enriched with TCR zeta-dim where CD8+, NK and CD4+CD28null 66 ACS; 32 stable angina Ammirati, 2008 [64] Th17 CD4+IL-17A+ ACS and Stable CAD Increased in AC with respect to stable CAD and controls 43 (ACS); 22 (stable CAD); 20 (controls) Cheng, 2008 [65] CD4+IL-17 + ACS and stable CAD No association 44 (ACS); 20 (stable CAD); 24 (controls) Zhao, 2011 [66] Th17/Th1 CD4+IL-17+IFN-γ+ ACS and stable CAD Increased in ACS 44 (ACS); 20 (stable CAD); 24 (controls) Zhao, 2011 [66] Th2 CD3+CD56−CD4+IL-4 + Carotid mean IMT and area, stroke and ACS Inverse correlation with carotid mean IMT and area, and with the risk of stroke and ACS evaluated prospectively 700 Engelbertsen, 2013 [59] ACS recurrence Elevated in patients suffering from ACS recurrence during 2-year follow-up 120 Liuzzo, 2007 [67] Tregs CD4+CD25+FoxP3+ ACS and stable CAD Reduced number in ACS, no correlation with stable CAD 40 ACS; 18 stable CAD; 20 controls Han, 2005 [68] CD4+CD25high ACS and stable CAD Reduced number and functionally compromised in ACS, no correlation for stable CAD 40 ACS; 28 stable CAD; 28 controls Mor, 2006 [69] CD4+CD25hiCD127lo Carotid IMT, stable CAD, ACS (ST-elevation and non-ST-elevation AMI) No correlation with IMT or IMT progression. No correlation in stable CAD. Reduced in non-ST elevation AMI, increased in ST-elevation AMI 113 carotid group; 200 coronary group (75 controls, 36 stable angina, 50 non-ST elevation AMI, 39 ST-elevation AMI) Ammirati, 2010 [70] CD3+CD4+CD25hiCD127loCCR5+ Carotid IMT, stable CAD, ACS (ST-elevation and non-ST-elevation AMI) No correlation with either CAD or carotid IMT 113 carotid group; 150 coronary group (25 controls, 36 stable angina, 50 Non-ST elevation AMI, 39 ST-elevation AMI) Ammirati, 2010 [70] T effector memory CD3+CD4+CD45RA−CD45RO+CCR7− Carotid IMT and CAD Correlation with IMT and association with CAD and cardiovascular risk factor 183 carotid group; 130 CAD group Ammirati, 2012 [47] CD4+CD45RA-CD45RO+ Carotid IMT and coronary arteries calcifications Positive correlation with carotid IMT and coronary arteries calcifications 912 Olson, 2013 [71] CD4+CD45RO+ Carotid IMT Positive correlation with carotid IMT 557 Tanigawa, 2003 [72] Circulating T cells . Subtype . Markers . Investigated condition . Finding . Number of patients . References . Th1 CD3+IFN-γ+ ACS and stable CAD Higher activation in ACS compared with stable CAD. Higher activation in ACS and stable CAD compared to controls 28 ACS; 18 stable CAD; 16 controls Methe, 2005 [58] CD3+CD56−CD4+IFN-γ+ ACS and stroke Inverse correlation with ACS and stroke risk evaluated prospectively 700 Engelbertsen, 2013 [59] CD4+CCR7− Stable and unstable angina Increased proportion in stable and unstable angina when compared to controls 40 stable angina; 40 unstable angina; 20 controls Damas, 2007 [33] HLA-DR+CD3+CD4+CD45RA−CD45RO+CCR7− Carotid IMT and CAD Correlation with IMT and association with CAD and cardiovascular risk factor 183 carotid group; 130 CAD group Ammirati, 2012 [60] CD3+HLA-DR+ Unstable and stable angina Increased in unstable angina compared to stable angina and controls 23 unstable angina; 13 chronic stable angina; 6 controls Caligiuri, 2000 [42] CD3+HLA-DR+ Unstable and stable angina Increased in unstable angina compared to stable angina and controls 29 stable angina; 36 stable angina; 30 controls Neri-Serneri, 1997 [61] CD4+CD28null CD4+CD28null Unstable angina and stable CAD Increased in unstable angina compared to stable CAD and controls 25 unstable angina; 25 stable angina; 21 hospitalized controls; 20 healthy controls Liuzzo, 1999 [62] CD4+CD28null ACS, stable angina and CVRF without CAD No differences among groups and with controls 20 ACS; 30 stable angina; 22 CVRF no CAD; 16 controls Teo, 2013 [63] TCR zeta-dim TCR zeta-dim ACS and chronic stable angina Increased proportion in ACS patients compared to chronic stable angina. Increase was higher in patients with higher C-reactive protein. Subsets enriched with TCR zeta-dim where CD8+, NK and CD4+CD28null 66 ACS; 32 stable angina Ammirati, 2008 [64] Th17 CD4+IL-17A+ ACS and Stable CAD Increased in AC with respect to stable CAD and controls 43 (ACS); 22 (stable CAD); 20 (controls) Cheng, 2008 [65] CD4+IL-17 + ACS and stable CAD No association 44 (ACS); 20 (stable CAD); 24 (controls) Zhao, 2011 [66] Th17/Th1 CD4+IL-17+IFN-γ+ ACS and stable CAD Increased in ACS 44 (ACS); 20 (stable CAD); 24 (controls) Zhao, 2011 [66] Th2 CD3+CD56−CD4+IL-4 + Carotid mean IMT and area, stroke and ACS Inverse correlation with carotid mean IMT and area, and with the risk of stroke and ACS evaluated prospectively 700 Engelbertsen, 2013 [59] ACS recurrence Elevated in patients suffering from ACS recurrence during 2-year follow-up 120 Liuzzo, 2007 [67] Tregs CD4+CD25+FoxP3+ ACS and stable CAD Reduced number in ACS, no correlation with stable CAD 40 ACS; 18 stable CAD; 20 controls Han, 2005 [68] CD4+CD25high ACS and stable CAD Reduced number and functionally compromised in ACS, no correlation for stable CAD 40 ACS; 28 stable CAD; 28 controls Mor, 2006 [69] CD4+CD25hiCD127lo Carotid IMT, stable CAD, ACS (ST-elevation and non-ST-elevation AMI) No correlation with IMT or IMT progression. No correlation in stable CAD. Reduced in non-ST elevation AMI, increased in ST-elevation AMI 113 carotid group; 200 coronary group (75 controls, 36 stable angina, 50 non-ST elevation AMI, 39 ST-elevation AMI) Ammirati, 2010 [70] CD3+CD4+CD25hiCD127loCCR5+ Carotid IMT, stable CAD, ACS (ST-elevation and non-ST-elevation AMI) No correlation with either CAD or carotid IMT 113 carotid group; 150 coronary group (25 controls, 36 stable angina, 50 Non-ST elevation AMI, 39 ST-elevation AMI) Ammirati, 2010 [70] T effector memory CD3+CD4+CD45RA−CD45RO+CCR7− Carotid IMT and CAD Correlation with IMT and association with CAD and cardiovascular risk factor 183 carotid group; 130 CAD group Ammirati, 2012 [47] CD4+CD45RA-CD45RO+ Carotid IMT and coronary arteries calcifications Positive correlation with carotid IMT and coronary arteries calcifications 912 Olson, 2013 [71] CD4+CD45RO+ Carotid IMT Positive correlation with carotid IMT 557 Tanigawa, 2003 [72] IFN = interferon; IL = interleukin; Th = T helper; NK = natural killer; TCR = T cell receptor; ACS = acute coronary syndromes; CAD = coronary artery disease; HLA-DR = human leucocyte antigen D-related; IMT = intima medial thickness; CVRF = cardiovascular risk factor; FoxP3 = forkhead box P3; AMI = acute myocardial infarction. Open in new tab Intraplaque T cell subsets CD4+ Th cells are abundant in atherosclerotic plaques. In response to combined stimulation with antigens, co-stimulators and specific cytokines, naive T cells differentiate into distinct effector or Th subsets, distinguished by cytokines they produce. The three best-characterized Th subsets are Th1, which secretes interferon (IFN)-γ, Th2, which secretes IL-4, IL-5 and IL-13, and Th17, which secretes IL-17 and IL-22. Chronic or repeated antigen exposure, which occurs during the course of atherosclerosis, generally results in the emergence of a dominant Th subset. In particular, compelling evidence has pointed to a role for Th1 and IFN-γ in promoting atherosclerosis and inflammation. Th1 is the most abundant T cell subtype in human atherosclerotic lesions [52], where they display signs of activation. In particular, they have been shown to secrete IFN-γ, TNF-α and IL-2, and to proliferate in situ [38]. Of importance, these cells secrete IFN-γ upon stimulation with oxLDL and LDL [45]. IFN-γ was in fact shown to promote atherosclerotic lesion development and destabilization in a variety of ways, including altering endothelial function, recruiting inflammatory cells within the lesion and interfering with cholesterol export from cells within the lesions [73]. IL-4, one of the master cytokines of Th2 subset, effectively inhibits Th1 differentiation and subsequent IFN-γ secretion [74], pointing to a possible protective role with regard to atherosclerosis, but definitive pathological evidence in humans is currently lacking [75]. The association between variants near the IL-5 gene locus and CAD has been demonstrated [76], suggesting a potential role of the Th2 subset in the modulation of development and progression of CAD. A putative atheroprotective effect has been suggested for IL-5 due to its negative correlation with carotid intima media thickness (IMT), a marker of subclinical atherosclerosis [77]. Th17 subsets were reported more recently to be associated with atherosclerosis [78,79], but their role remains debated. In particular, the production of IL-17A by lesional T cells was shown to associate with plaque inflammation and instability [53]. In humans, a CD28null subset of CD4+ T cells proliferate in the setting of inflammatory disease, cytomegalovirus infection and advanced age. These cells elaborate proinflammatory cytokines, including IFN-γ, and exhibit cytotoxicity [80]. Clonally expanded CD28nullCD4+ cells were found in unstable coronary plaques, where they may sustain and augment the inflammatory process [43]. Many of these cells specifically recognize HSP60, and display a high expression of members of the TNF family receptors, e.g. OX40 (CD 131), which may act as alternative co-stimulatory receptors [81]. In addition, these cells were shown to be resistant regulatory T cells (Tregs) to suppression in vitro [81]. They comprise a number of CD4+ T cell subsets with immunosuppressive properties that play an essential role in self-tolerance and protection against autoimmunity [82]. Tregs comprise approximately 1–5% of all T cells within atherosclerotic lesions, which is less than ≤25% found generally in other chronically inflamed tissues [54]. While some studies show a reduced number of Tregs in unstable plaques [83], suggesting an atheroprotective role for their anti-inflammatory immune regulator function, others challenge this view, reporting a higher number of Tregs in lesions at risk [55], which may be attributable to an altered Treg functional state or to a compensatory increase of Tregs to counterbalance a T cell activation at the plaque level. A recent report by Klingenberg and colleagues showed an increased number of Tregs in coronary artery thrombus aspirate from 16 ACS patients compared to circulating Tregs from the same patients or healthy controls [56]. Interestingly, T cells within the thrombus showed restricted TCR expression: together these data support differential, antigen-driven trapping of Tregs in the thrombus as a consequence of ACS [56]. CD8+ cytotoxic T cells are generally less abundant than CD4+ cells in human atherosclerotic plaques. None the less, they can constitute up to 50% of cells in advanced lesions, suggesting a potential role in plaque inflammation and instability [84]. Natural killer T (NK T) cells constitute a distinct subset of T cells expressing both natural killer and T cell markers. They are activated upon stimulation by lipid antigens presented through the MHC-I-like molecule CD1d, which renders them particularly interesting in the study of atherosclerosis [85]. Human atheroma contains cells that display CD1 [86] as well as NK T cells [57], suggesting a pro-atherogenic role for this T cell subtype. Circulating T cell subpopulations Considering the systemic nature of the immune response in atherosclerosis, analysis of the circulating T cell subpopulation by means of flow cytometry provides a viable option for its characterization in humans. While this approach has gained widespread popularity due to its reliability and low intrinsic invasiveness, methodological caveats need to be taken into consideration: in particular, trafficking of T cells between lesions, blood and secondary lymphoid organs may hamper the interpretation of the blood count at a certain time-point [87]. Accordingly, thoracic lymph nodes of patients with CAD revealed a lymphocyte subpopulation profile differing substantially from that of blood, including a higher proportion of B cells, lower proportions of CD8+ T cells, a twofold higher CD4/CD8 ratio and an enrichment of CD4+CD69+ cells, as well as Tregs [88]. Peripheral blood of CVD patients shows an increased proportion of effector memory T cells (TEM), defined as CD3+CD4+CD45RA−CD45RO+CCR7−, which correlated with the extent of atherosclerotic disease in the coronary and carotid districts [47] (see Table 1). Consistent with this result, other studies documented an increase of CCR7− T cells in patients with CAD [33] and an increase of memory T cells in patients with subclinical carotid atherosclerosis [71,72]. TEM emerged as the T cell subset with the strongest association with atherosclerosis in carotid and coronary vascular districts at different stages of disease. TEM correlated significantly with plasma total cholesterol and LDL cholesterol, although the association between TEM and carotid atherosclerosis was independent of the classical CVRFs, supporting the relevance of adaptive immune response in CV disorders [47,89]. TEM cells, together with central memory T cells (TCM), persist in the memory pool once the antigen that elicited an immune response has been eliminated. They retain the memory of (i) antigen specificity, (ii) the array of cytokines they have produced and (iii) the site where their effector function is needed. Upon antigen re-exposure, TEM display immediate effector functions in inflamed peripheral tissues (in this case the atherosclerotic plaque), mainly by the expression of CCR5 and CXCR3 [90]. The expression of HLA-DR constitutes a marker of effector function acquisition, and several studies documented an increase of activated HLA-DR+ T cells in patients with CAD [42,47,61]. Th1 cells were shown to be more abundant in the blood of patients suffering from ACS [58,66], but it is yet to be determined whether this reflects an acute response to myocardial damage or the underlying CAD. In addition, a subset of INF-γ-secreting Th17 cells, namely Th1/Th17 cells, was shown to be associated with the development of ACS [66], further supporting the role for IFN-γ in atherosclerosis. Th17 themselves have been associated with an increased risk of CVD, although inconsistently [65,66]. A recent retrospective study demonstrated a negative correlation between circulating Th2 cells and common carotid intima media thickness (IMT) and the risk of cardiovascular events, along with a negative association between Th1 cell count and the development of atherosclerosis-related complications [59]. During ACS, the classical immunological synapse mediated by antigen–TCR engagement (signal 1) and co-stimulatory receptors such as CD28, that mediate signal 2, are perturbed in circulating T cells [91]. In fact CD3+CD4+TCR zeta-dim, i.e. a T cell subset with decreased levels of the zeta subunit of TCR, also called CD247, which couples the engaged TCR–CD3 complex to downstream intracellular signal transduction pathways, and CD4+CD28null T cells were found to be higher in patients suffering from ACS [62,64]. Interestingly, higher circulating levels of CD4+CD28null cells were found to associate with poor prognosis upon recurrence of ACS [67]. Down-regulation of the TCR zeta chain and CD28 generally occur after antigen engagement or in response to inflammatory stimuli as a feedback mechanism aimed at tuning the immune response. Together with CD28 down-regulation, TCR zeta chain reduction was observed in T cells isolated in several chronic diseases, including cancer, autoimmune, e.g. systemic lupus erythematosus (SLE), and infectious diseases [92]. Given that intact TCR signalling is critical to maintain immune homeostasis through the generation and functioning of regulatory T cell subsets, alterations in signal 1 pathways could result in increased TCR zeta-dim T cells which, in turn, could dampen modulator feedback signals, thus potentially limiting CD4+CD28null T cell responsiveness to inhibition. Both TCR zeta-dim T cells and CD4+CD28null T cells can respond to stimuli independently of the antigen-mediated TCR pathway [93,94]. Furthermore, human circulating or plaque CD4+CD28null T cells from ACS patients express IL-12 receptors even in the absence of antigenic stimulation, and up-regulate the expression of the chemokine receptor CCR5 and the C-type lectin receptor CD161, both implicated in regulating tissue homing of effector T cells after IL-12 stimulation [93]. This suggests that CD4+CD28null T cells could functionally resemble NK cells, with proinflammatory activity even in the unprimed state and increased tissue trafficking and homing after IL-12-inducing host infection associated with accrual in inflammatory lesions. Both antigen-dependent and -independent mechanisms are therefore thought to be critical to elicit responses in CD28 and/or TCR zeta chain defective memory T cell subsets, thus promoting a proinflammatory and pro-atherosclerotic response [91]. Adaptive immunity can operate during atherogenesis as a ‘double-edged sword’, exerting both promoting and inhibitory effects on plaques [95]. Regarding the anti-inflammatory or anti-atherosclerotic side of T cell function, analysis of circulating Tregs has yielded contrasting results. ACS patients were shown to have lower levels of CD4+CD25+forkhead box protein 3 (FoxP3+) circulating T cells [68], and Tregs isolated from the blood of ACS patients displayed a reduced ability to suppress oxLDL-induced CD+CD25− proliferation [69]. No significant association was found, however, with the extension of atherosclerotic disease in stable CAD patients [68,69]. A subsequent report confirmed the lack of association between stable CAD extent and progression and the levels of circulating Tregs, defined as CD4+CD25hiCD127lo, and established an association between ST-elevated AMI and high levels of Tregs [70]. A more prominent inflammatory activation in ST-elevated AMI patients, as documented by increased IL-6 levels [60], might account for a proportional compensatory Treg counterbalance, similarly to the observed IL-10 increase [60]. In contrast, patients suffering from non-ST-elevated ACS were shown to have reduced circulating levels of Tregs [70]. Finally, as CCR5 not only drives effector T cells but also Tregs homing and trafficking in inflamed non-lymphoid tissue [96], suggesting that CCR5+ Tregs constituted a subgroup of ‘effector’ Treg cells, levels of circulating CCR5+ Tregs were assessed in both patients with subclinical carotid and CAD. Analysis of 313 individuals did not show any association between CCR5+ Tregs and atherosclerosis [70]. Despite challenging findings in humans, the complex role of Tregs in atherosclerosis is currently under investigation, supported by promising data on the atheroprotective role of this T cell subset obtained in murine models [97]. B cells and humoral response in atherosclerosis While the role of T cells in atherosclerosis has been studied extensively over decades, the role of B cells has only recently begun to gain attention. The first cue for B cell involvement in the pathogenesis of atherosclerotic lesions has spread from animal studies [98], but currently evidence is also building in humans. A recent network-driven integrative analysis of data from genomewide association studies and whole blood gene expression profiles from Framingham Heart Study participants identified B cell immune responses as causative for CAD [99]. In contrast to T cells, only few B cells can be detected locally within the atheroma [44], while a large number can be found in the adventitial layer of atherosclerotic vessels, where they display a structural organization closely resembling a tertiary lymphoid organ [100], which is consistent with the presence of chronic immune response. B cells in atherosclerotic lesions were shown to be oligoclonal and undergoing antigen-driven proliferation [101]. Such an antigen-driven B cell response is Th-cell dependent, delayed, and results in the production of high-affinity antibodies undergoing class switch. The entire process occurs in specialized structures within lymphoid organs, namely germinal centres. A specific subset of Th cells, known as T follicular helper cells (Tfh), was shown to be responsible for germinal centre organization and for providing B cells with the help required for proliferation and affinity maturation [102]. Tfh cells were shown to express lower amounts of cytokines, but also a higher variety of surface receptors, such as CD40L (CD154) or OX-40, when compared to other Th cell subsets [102]. The role of Tfh cells in atherosclerosis has not yet been investigated. B cells responsible for this type of response originate from the bone marrow, and are known as B2 cells [103]. Antibodies secreted by B2 cells comprise all human immunoglobulin (Ig) classes, namely IgM, IgG, IgE and IgA. IgG antibodies directed against OSEs, in particular aldehyde-modified peptide sequences of apolipoprotein B-100, can be detected readily in the sera of atherosclerotic patients [104]. In addition, self-reacting IgG against transgelin (TAGLN), a cytoskeletal protein, were shown to be secreted by B2 cells located within carotid artery plaques [44]. Interestingly, these antibodies were shown to cross-react with antigenic determinants of the bacterial wall of Gram-negative bacteria belonging to the Enterobacteriaceae family, again supporting a potential role for infection in the development of atherosclerosis [44]. Further studies are needed to deepen our understanding of the role and association with the CV risk of IgG and IgM against OSEs and other antigens that can be detected in the atherosclerotic plaques [75]. Apart from the production of atherogenic antibodies, experimental studies showed that B2 cells appear to aggravate atherogenesis through antibody-independent mechanisms that augment the action of proinflammatory cytokines [105]. IgA immunoglobulins can be found on mucosal surfaces, where they provide the first line of defence against pathogens, and at lower concentrations in the circulation. Although there is little information about the role of IgA in atherosclerosis, there appears to be an association between high serum IgA titres and advanced vascular disease and myocardial infarction [106]. While, currently, no mechanism has been proposed to explain such association, recent data in the role of gut microbiome in CVD [107,108] may potentially provide new insights in the role of IgA in atherosclerosis. Alongside B2 cells, humans have a minor B cell subset, called B1 cells, comprised of long-lived, non-circulating cells found preferentially in the spleen and the peritoneal or pleural cavity [103]. These cells secrete poorly specific natural IgM antibodies, setting up a rapid and T cell-independent humoral response. B1 secreted antibodies are polyreactive and constitute a first line of defence against pathogens. Natural IgM antibodies make up a substantial proportion of IgM in the uninfected human, and up to 30% of them are directed specifically against OSEs [24]. Several clinical studies have shown that titres of such naturally occurring OSE-specific IgM correlate inversely with atherosclerotic burden estimated by carotid artery IMT [104,109,110], as well as with the risk of stroke and AMI [111]. The atheroprotective mechanism of natural IgM is yet to be elucidated, but experimental studies suggest that these antibodies prevent oxLDL internalization by macrophages and limit the accumulation of apoptotic cells by augmenting efferocytosis [112] (Fig. 2). Table 3 summarizes the main findings concerned with B cell and humoral response in atherosclerosis. Fig. 2 Open in new tabDownload slide Role of B cells and Immunoglobulins in atherosclerotic lesion development. Under chronic inflammatory conditions, B2 cells become activated by T follicular helper cells within lymphoid-like structures in the vessel wall. They undergo maturation into antibody secreting cells within the plaque where they directly secrete immunoglobulins. Further immunoglobulins, including B1 cell-secreted naturally occurring antibodies, are secreted in other districts and reach the plaque through the systemic circulation. The presence of B1 cells within the plaque is currently a matter of debate. Immunoglobulins show a wide range of specificities, including oxidized low-density lipoproteins (oxLDL) and heat shock protein 60 (HSP60). Naturally occurring immunoglobulin (Ig)M appears to exert a protective action by inhibiting the uptake of oxLDL by macrophages and by favouring the clearance of apoptotic bodies, which is aided by local deposition of complement. Conversely, IgG directed against oxLDL may enhance the uptake of cholesterol, thus favouring atherosclerosis. A protective effect, however, was shown for IgG specific for peptide 210 of ApoB100. IgG cross-reacting with bacterial antigens were shown to be produced within lesione, suggesting a role for infectious agents. IgG recognizing endothelial antigens, e.g. HSP60, may directly cause endothelial disfunction. SMC = smooth muscle cells. Fig. 2 Open in new tabDownload slide Role of B cells and Immunoglobulins in atherosclerotic lesion development. Under chronic inflammatory conditions, B2 cells become activated by T follicular helper cells within lymphoid-like structures in the vessel wall. They undergo maturation into antibody secreting cells within the plaque where they directly secrete immunoglobulins. Further immunoglobulins, including B1 cell-secreted naturally occurring antibodies, are secreted in other districts and reach the plaque through the systemic circulation. The presence of B1 cells within the plaque is currently a matter of debate. Immunoglobulins show a wide range of specificities, including oxidized low-density lipoproteins (oxLDL) and heat shock protein 60 (HSP60). Naturally occurring immunoglobulin (Ig)M appears to exert a protective action by inhibiting the uptake of oxLDL by macrophages and by favouring the clearance of apoptotic bodies, which is aided by local deposition of complement. Conversely, IgG directed against oxLDL may enhance the uptake of cholesterol, thus favouring atherosclerosis. A protective effect, however, was shown for IgG specific for peptide 210 of ApoB100. IgG cross-reacting with bacterial antigens were shown to be produced within lesione, suggesting a role for infectious agents. IgG recognizing endothelial antigens, e.g. HSP60, may directly cause endothelial disfunction. SMC = smooth muscle cells. Table 3 Summary of main findings regarding humoral response in human atherosclerosis B cell type . Immunoglobulin class . Specificity . Finding . Number of patients . Reference . B1 IgM Naturally occurring, specific to various OSEs Inverse correlation with carotid artery IMT and number of plaques 1022 Karvonen, 2003 [109] Association with lower CVD and stroke risk 765 Tsimikas, 2012 [111] B2 IgM ApoB100 peptide 210 Negative correlation with carotid artery IMT severity and progression during 30 months 3430 McLeod, 2014 [113] IgG ApoB100 peptide 210 Negative correlation with carotid artery IMT severity and progression during 30 months 3430 McLeod, 2014 [113] Polyclonal anti-OSEs Positive correlation with presence of angiographically determined CAD. Loss of significance upon correction for other risk factors 504 Tsimikas, 2007 [114] TAGLN (human cytoskeletal protein) Locally produced within carotid artery plaques. Cross-react against bacterial atigens 4 Canducci, 2012 [44] IgE – Correlation with risk of AMI and sudden death in dyslipidaemic men 135 Kovanen, 1998 [106] Higher in CAD patients than in controls. Among CAD patient, higher in AMI than in unstable angina, and higher in unstable than in stable angina 709 CAD; 273 controls Wang, 2011 [115] IgA – Correlation with risk of AMI and sudden death in dyslipidaemic men 135 Kovanen, 1998 [106] Increased in ACS patients compared to controls 145 ACS; 34 controls Muscari 1988 [116] B cell type . Immunoglobulin class . Specificity . Finding . Number of patients . Reference . B1 IgM Naturally occurring, specific to various OSEs Inverse correlation with carotid artery IMT and number of plaques 1022 Karvonen, 2003 [109] Association with lower CVD and stroke risk 765 Tsimikas, 2012 [111] B2 IgM ApoB100 peptide 210 Negative correlation with carotid artery IMT severity and progression during 30 months 3430 McLeod, 2014 [113] IgG ApoB100 peptide 210 Negative correlation with carotid artery IMT severity and progression during 30 months 3430 McLeod, 2014 [113] Polyclonal anti-OSEs Positive correlation with presence of angiographically determined CAD. Loss of significance upon correction for other risk factors 504 Tsimikas, 2007 [114] TAGLN (human cytoskeletal protein) Locally produced within carotid artery plaques. Cross-react against bacterial atigens 4 Canducci, 2012 [44] IgE – Correlation with risk of AMI and sudden death in dyslipidaemic men 135 Kovanen, 1998 [106] Higher in CAD patients than in controls. Among CAD patient, higher in AMI than in unstable angina, and higher in unstable than in stable angina 709 CAD; 273 controls Wang, 2011 [115] IgA – Correlation with risk of AMI and sudden death in dyslipidaemic men 135 Kovanen, 1998 [106] Increased in ACS patients compared to controls 145 ACS; 34 controls Muscari 1988 [116] AMI = acute myocardial infarction; ACS = acute coronary syndromes; CAD = coronary artery disease; Ig = immunoglobulin; IMT = intima medial thickness; CVD = cardiovascular disease; OSE = oxidation-specific epitope. Open in new tab Table 3 Summary of main findings regarding humoral response in human atherosclerosis B cell type . Immunoglobulin class . Specificity . Finding . Number of patients . Reference . B1 IgM Naturally occurring, specific to various OSEs Inverse correlation with carotid artery IMT and number of plaques 1022 Karvonen, 2003 [109] Association with lower CVD and stroke risk 765 Tsimikas, 2012 [111] B2 IgM ApoB100 peptide 210 Negative correlation with carotid artery IMT severity and progression during 30 months 3430 McLeod, 2014 [113] IgG ApoB100 peptide 210 Negative correlation with carotid artery IMT severity and progression during 30 months 3430 McLeod, 2014 [113] Polyclonal anti-OSEs Positive correlation with presence of angiographically determined CAD. Loss of significance upon correction for other risk factors 504 Tsimikas, 2007 [114] TAGLN (human cytoskeletal protein) Locally produced within carotid artery plaques. Cross-react against bacterial atigens 4 Canducci, 2012 [44] IgE – Correlation with risk of AMI and sudden death in dyslipidaemic men 135 Kovanen, 1998 [106] Higher in CAD patients than in controls. Among CAD patient, higher in AMI than in unstable angina, and higher in unstable than in stable angina 709 CAD; 273 controls Wang, 2011 [115] IgA – Correlation with risk of AMI and sudden death in dyslipidaemic men 135 Kovanen, 1998 [106] Increased in ACS patients compared to controls 145 ACS; 34 controls Muscari 1988 [116] B cell type . Immunoglobulin class . Specificity . Finding . Number of patients . Reference . B1 IgM Naturally occurring, specific to various OSEs Inverse correlation with carotid artery IMT and number of plaques 1022 Karvonen, 2003 [109] Association with lower CVD and stroke risk 765 Tsimikas, 2012 [111] B2 IgM ApoB100 peptide 210 Negative correlation with carotid artery IMT severity and progression during 30 months 3430 McLeod, 2014 [113] IgG ApoB100 peptide 210 Negative correlation with carotid artery IMT severity and progression during 30 months 3430 McLeod, 2014 [113] Polyclonal anti-OSEs Positive correlation with presence of angiographically determined CAD. Loss of significance upon correction for other risk factors 504 Tsimikas, 2007 [114] TAGLN (human cytoskeletal protein) Locally produced within carotid artery plaques. Cross-react against bacterial atigens 4 Canducci, 2012 [44] IgE – Correlation with risk of AMI and sudden death in dyslipidaemic men 135 Kovanen, 1998 [106] Higher in CAD patients than in controls. Among CAD patient, higher in AMI than in unstable angina, and higher in unstable than in stable angina 709 CAD; 273 controls Wang, 2011 [115] IgA – Correlation with risk of AMI and sudden death in dyslipidaemic men 135 Kovanen, 1998 [106] Increased in ACS patients compared to controls 145 ACS; 34 controls Muscari 1988 [116] AMI = acute myocardial infarction; ACS = acute coronary syndromes; CAD = coronary artery disease; Ig = immunoglobulin; IMT = intima medial thickness; CVD = cardiovascular disease; OSE = oxidation-specific epitope. Open in new tab Platelet adhesion, thrombosis and adaptive immunity Thrombosis is a critical event in the natural history of atherosclerosis. Rupture or erosion of advanced, vulnerable lesions exposes the highly thrombogenic subendothelial layer and initiates platelet adhesion and thrombosis, resulting in acute complications such as ACS or stroke [117]. In addition, many indications suggest that platelets may contribute actively to neointimal formation and atherosclerotic lesion initiation and progression [118] [119]. Several lines of evidence functionally link lymphocytes and platelets in the development and clinical manifestations of atherosclerosis. In particular, lymphocyte master cytokines such as IFN-γ and IL-4 were shown to associate significantly with residual platelet reactivity in ACS patients on dual anti-platelet therapy [120], pointing to a role for T cell effector function in the development of thrombosis. Experimental studies have shown that IFN-γ can enhance platelet-dense granule secretion and conjugation with lymphocytes [121], and IL-2 was shown to reduce platelet adhesion and increase α-granule secretion [122]. Furthermore, lymphocyte ecto-ATPase may convert ATP released extracellularly by platelets themselves or other cell types into ADP, which subsequently enhances platelet aggregation [123]. Notably, however, the interaction of platelets and lymphocytes appears to be bidirectional, and platelets appear to modulate various aspect of lymphocyte function and to influence their engagement in atherosclerosis. Platelets can adhere to lymphocytes to form platelet–lymphocyte conjugates [124], which may facilitate the adhesion of lymphocytes under sheer stress conditions [125] and recruit them in sites of arterial thrombi [126]. Platelets were shown to enhance T cell cytokine production, mainly through a cell-to-cell interaction mediated by CD40–CD40L (CD154) ligation [127], and to arrest CD4+ T cell clonal expansion by favouring their differentiation into effector cells by multiple cell-to-cell interactions and soluble mediators [128]. Platelets were also shown to directly stimulate B cell proliferation and supprt isotype switching [127]. Atherosclerosis and disorders of the immune system The profound involvement of adaptive immunity in atherosclerotic disease is confirmed further by the increased risk of CVD in patients affected by disorders of the immune system, including autoimmune diseases and HIV. Autoimmune diseases are a group of disorders characterized by loss of immunological tolerance with subsequent humoral and cell-mediated immune responses against self-constituents. Such disorders, which include SLE and rheumatoid arthritis (RA) among others, are associated with an accelerated progression of atherosclerosis and excess CV morbidity and mortality not accounted for fully by traditional CVRF [129,130]. The specific underlying mechanism of increased risk is yet to be defined, but appears to involve both aspecific inflammation and immune activation. In SLE, titres of autoantibodies, correlate with atherosclerosis development and progression and the risk of ACS [129]. A thorough analysis of circulating T cells showed a greater proportion of activated cells, i.e. HLA-DR+ and CCR5+ cells, in SLE patients, which paralleled a faster progression of atherosclerosis, but no significant association was established between T cell profile and CVD [131]. Similarly, RA is associated with higher risk for CAD and with higher ACS mortality and recurrence rates [130]. Interestingly, RA patients suffering from atherosclerosis were shown to have a disproportionate expansion of CD28nullCD4+ T cells, alongside Th17/Treg imbalance [132]. In addition, patients positive for anti-cyclic citrullinated peptide IgG autoantibodies were shown to be at increased risk for atherosclerosis progression with respect to RA patients negative for the same autoantibody and healthy individuals [133]. Citrullinated peptides, which form in the face of active inflammation, were shown to be abundant in atherosclerotic lesions [133]. Chronic HIV infection, which is well known to depress immune function of the host, is associated with a high risk of vascular atherosclerotic disease, progressing rapidly from endothelial dysfunction to subclinical atherosclerosis and, in some cases, to advanced disease and ACS [134]. The drivers of the spectrum of vascular disease in HIV patients are complex and incompletely understood, and appear to involve both medication-related elements [135] and chronic inflammation with lymphocyte activation secondary to the loss of CD4+ T cells induced by the virus [136]. In particular, generalized CD4+ T cell activation as well as CD8+ T cell activation and senescence were shown to correlate positively with subclinical atherosclerosis in HIV-infected individuals treated with an effective anti-retroviral therapy [137]. Immune system modulation for the treatment and prevention of atherosclerosis Apart from new insights into the pathogensis of CVD, study of the immunological mechanisms of atherosclerosis has provided clues for the development of novel treatments aimed at modulating immunity to improve patient outcomes. The identification of autoantigens involved in atherogenesis led to the proposal that immunization against them may lead to the alleviation of atherosclerotic disease [138]. Vaccination against a number of oxLDL-associated OSEs was shown to reduce lesions in animal models, although whether a similar approach would be effective in humans is yet to be proved [138]. Experimental studies in mice identified antigen-specific Tregs as a critical component of immunization-induced atheroprotection [139]. OxLDL is a complex particle, and may contain many relevant epitopes. Screening for immunogenic LDL-derived epitopes has identified a set of peptides which were used for immunization in mice [140]. The few displaying an atheroprotective activity are currently undergoing extensive study to develop experimental vaccines. Experimental studies provide evidence for the reduction of atherosclerotic vascular disease by direct inhibition of pathogenic cytokines or their receptors [75]. Consistent with this strategy, the ongoing Canakinumab Anti-inflammatory Thrombosis Outcome Study is aimed at evaluating the impact of IL-1β blockage on AMI recurrence and atherosclerosis progression in AMI patients [141]. Preliminary data have shown that Canakinumab, a human monoclonal antibody that neutralizes interleukin-1β, significantly reduces inflammation, measured as C-reactive protein and IL-6 levels, without major effects on LDL or HDL cholesterol [142]. In addition, prospective observational data from patients affected by autoimmune diseases treated with anti-cytokine medications will probably provide insights into the impact of such interventions on CVD. Other potential stategies that have currently proved effective in animal studies include modulation of co-stimulatory and co-inhibitory signals and T cell deple tion, although the latter is unlikely to ever be translated into clinical practice due to excessive immunosuppression. The advent and clinical application of B cell-targeted compounds in autoimmune disease and onco-haematology offers a great opportunity for novel therapeutic strategies in atherosclerosis. Among these, rituximab is a B cell-depleting antibody currently approved for use in lymphomas and RA that acts through the cross-linking of B cell-specific surface antigen CD20 [143]. Belimumab is a monoclonal antibody that neutralizes the cytokine B cell activating factor (BAFF), which is essential for B cell survival and maturation [144]. The effect of both of these therapies on CVD, in particular in patients with autoimmune disorders, is currently unknown, but experimental evidence demonstrated an atheroprotective effect for both [145,146]. Conclusions The evidence summarized above supports a role for the operation of adaptive immune response in atherosclerotic lesion development and clinical manifestations. Apart from providing new fascinating insights in the pathogenesis of CVD, recognition of the immunological mechanisms in atherogenesis has provided the rationale for the development of novel therapeutical strategies for the treatment of atherosclerosis and its clinical manifestations. However, in the clinical setting this approach presents major challenges, as global interference with host defence mechanisms can yield an immunosuppressed individual, at high risk for cancer and opportunistic infections. Furthermore, to date no trial with any anti-inflammatory agent was able to reduce CV mortality. The recent negative results of darapladib [147], an oral selective inhibitor of the lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme able to generate OSEs and inflammatory mediators directly from LDLs, challenges some hypotheses derived from animal models, where LDLs modified by Lp-PLA2 acquire potent pro-atherogenic activities [148]. Finally, it should not be forgotten that hypercholesterolaemia per se remains the single most important driver for the primary inflammatory cascade and subsequent immune response, and that clinical studies have demonstrated that lowering plasma cholesterol effectively reduces inflammation [149]. In addition, the measurement of C-reactive protein with a 2 mg/l cut-off would not have predicted 41% of unequivocally documented ST-elevation AMIs, thus indicating both its limitations as an individual prognostic marker and as an indicator of a generalized inflammatory pathogenetic component in AMI [150]. Further research is therefore needed to unwind the complexity of atherosclerosis-associated immune response and the inter-relation between immunity and dyslipidaemia, in order to limit atherosclerotic disease most effectively. Acknowledgements Enrico Ammirati received financial support from the ‘Giovane Ricercatore 2009 Grant’ from Italian Health Ministry (project code GR-2009–1608780). Disclosure The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Author contributions E. A. and F. M. wrote the report. M. M. and P. G. C. crically revised the manuscript. References 1 Murray CJ , Vos T, Lozano R et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 . Lancet 2012 ; 380 : 2197 – 2223 . Google Scholar Crossref Search ADS PubMed WorldCat 2 Go AS , Mozaffarian D, Roger VL et al. Heart disease and stroke statistics – 2014 update: a report from the American Heart Association . Circulation 2014 ; 129 : e28 – e292 . Google Scholar PubMed OpenURL Placeholder Text WorldCat 3 Libby P . Mechanisms of acute coronary syndromes and their implications for therapy . N Engl J Med 2013 ; 368 : 2004 – 2013 . Google Scholar Crossref Search ADS PubMed WorldCat 4 Kannel WB , Dawber TR, Friedman GD, Glennon WE, McNamara PM. Risk factors in coronary heart disease. An evaluation of several serum lipids as predictors of coronary heart disease; the Framingham Study . Ann Intern Med 1964 ; 61 : 888 – 899 . Google Scholar Crossref Search ADS PubMed WorldCat 5 Gordon T , Castelli WP, Hjortland MC, Kannel WB, Dawber TR. Predicting coronary heart disease in middle-aged and older persons. The Framington Study . JAMA 1977 ; 238 : 497 – 499 . Google Scholar Crossref Search ADS PubMed WorldCat 6 Mihaylova B , Emberson J, Blackwell L et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials . Lancet 2012 ; 380 : 581 – 590 . Google Scholar Crossref Search ADS PubMed WorldCat 7 Turnbull F . Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials . Lancet 2003 ; 362 : 1527 – 1535 . Google Scholar PubMed OpenURL Placeholder Text WorldCat 8 Fichtenberg CM , Glantz SA. Association of the California Tobacco Control Program with declines in cigarette consumption and mortality from heart disease . N Engl J Med 2000 ; 343 : 1772 – 1777 . Google Scholar Crossref Search ADS PubMed WorldCat 9 Helgadottir A , Thorleifsson G, Manolescu A et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction . Science 2007 ; 316 : 1491 – 1493 . Google Scholar Crossref Search ADS PubMed WorldCat 10 McPherson R , Pertsemlidis A, Kavaslar N et al. A common allele on chromosome 9 associated with coronary heart disease . Science 2007 ; 316 : 1488 – 1491 . Google Scholar Crossref Search ADS PubMed WorldCat 11 Libby P , Ridker PM, Maseri A. Inflammation and atherosclerosis . Circulation 2002 ; 105 : 1135 – 1143 . Google Scholar Crossref Search ADS PubMed WorldCat 12 Paragh G , Seres I, Harangi M, Fulop P. Dynamic interplay between metabolic syndrome and immunity . Adv Exp Med Biol 2014 ; 824 : 171 – 190 . Google Scholar Crossref Search ADS PubMed WorldCat 13 Frostegard J . Immune mechanisms in atherosclerosis, especially in diabetes type 2 . Front Endocrinol (Lausanne) 2013 ; 4 : 1 – 11 . Google Scholar Crossref Search ADS PubMed WorldCat 14 Sarwar N , Butterworth AS, Freitag DF et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies . Lancet 2012 ; 379 : 1205 – 1213 . Google Scholar PubMed OpenURL Placeholder Text WorldCat 15 Getz GS , Reardon CA. Animal models of atherosclerosis . Arterioscler Thromb Vasc Biol 2012 ; 32 : 1104 – 1115 . Google Scholar Crossref Search ADS PubMed WorldCat 16 Bentzon JF , Falk E. Atherosclerotic lesions in mouse and man: is it the same disease? Curr Opin Lipidol 2010 ; 21 : 434 – 440 . Google Scholar Crossref Search ADS PubMed WorldCat 17 Weber C , Noels H. Atherosclerosis: current pathogenesis and therapeutic options . Nat Med 2011 ; 17 : 1410 – 1422 . Google Scholar Crossref Search ADS PubMed WorldCat 18 Cannon CP , Braunwald E, McCabe CH et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome . N Engl J Med 2005 ; 352 : 1646 – 1654 . Google Scholar Crossref Search ADS PubMed WorldCat 19 Grayston JT , Kronmal RA, Jackson LA et al. Azithromycin for the secondary prevention of coronary events . N Engl J Med 2005 ; 352 : 1637 – 1645 . Google Scholar Crossref Search ADS PubMed WorldCat 20 Song Z , Brassard P, Brophy JM. A meta-analysis of antibiotic use for the secondary prevention of cardiovascular diseases . Can J Cardiol 2008 ; 24 : 391 – 395 . Google Scholar Crossref Search ADS PubMed WorldCat 21 Smeeth L , Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination . N Engl J Med 2004 ; 351 : 2611 – 2618 . Google Scholar Crossref Search ADS PubMed WorldCat 22 Grundtman C , Kreutmayer SB, Almanzar G, Wick MC, Wick G. Heat shock protein 60 and immune inflammatory responses in atherosclerosis . Arterioscler Thromb Vasc Biol 2011 ; 31 : 960 – 968 . Google Scholar Crossref Search ADS PubMed WorldCat 23 Duewell P , Kono H, Rayner KJ et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals . Nature 2010 ; 464 : 1357 – 1361 . Google Scholar Crossref Search ADS PubMed WorldCat 24 Miller YI , Choi SH, Wiesner P et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity . Circ Res 2011 ; 108 : 235 – 248 . Google Scholar Crossref Search ADS PubMed WorldCat 25 Tabas I . Macrophage death and defective inflammation resolution in atherosclerosis . Nat Rev Immunol 2010 ; 10 : 36 – 46 . Google Scholar Crossref Search ADS PubMed WorldCat 26 Deloukas P , Kanoni S, Willenborg C et al. Large-scale association analysis identifies new risk loci for coronary artery disease . Nat Genet 2013 ; 45 : 25 – 33 . Google Scholar Crossref Search ADS PubMed WorldCat 27 Kojima Y , Downing K, Kundu R et al. Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis . J Clin Invest 2014 ; 124 : 1083 – 1097 . Google Scholar Crossref Search ADS PubMed WorldCat 28 Clarke MC , Talib S, Figg NL, Bennett MR. Vascular smooth muscle cell apoptosis induces interleukin-1-directed inflammation: effects of hyperlipidemia-mediated inhibition of phagocytosis . Circ Res 2010 ; 106 : 363 – 372 . Google Scholar Crossref Search ADS PubMed WorldCat 29 Steinman RM . Decisions about dendritic cells: past, present, and future . Annu Rev Immunol 2012 ; 30 : 1 – 22 . Google Scholar Crossref Search ADS PubMed WorldCat 30 Bakdash G , Sittig SP, van Dijk T, Figdor CG, de Vries IJ. The nature of activatory and tolerogenic dendritic cell-derived signal II . Front Immunol 2013 ; 4 : 1 – 18 . Google Scholar Crossref Search ADS PubMed WorldCat 31 Hermansson A , Ketelhuth DF, Strodthoff D et al. Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis . J Exp Med 2010 ; 207 : 1081 – 1093 . Google Scholar Crossref Search ADS PubMed WorldCat 32 Sage A , Murphy DM, Maffia P et al. MHC class II-restricted antigen presentation by plasmacytoid dendritic cells drives pro-atherogenic T cell immunity . Circulation 2014 ; 130 : 1363 – 1373 . Google Scholar Crossref Search ADS PubMed WorldCat 33 Damas JK , Smith C, Oie E et al. Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization . Arterioscler Thromb Vasc Biol 2007 ; 27 : 614 – 620 . Google Scholar Crossref Search ADS PubMed WorldCat 34 Cybulsky MI , Jongstra-Bilen J. Resident intimal dendritic cells and the initiation of atherosclerosis . Curr Opin Lipidol 2010 ; 21 : 397 – 403 . Google Scholar Crossref Search ADS PubMed WorldCat 35 Dietel B , Cicha I, Voskens CJ, Verhoeven E, Achenbach S, Garlichs CD. Decreased numbers of regulatory T cells are associated with human atherosclerotic lesion vulnerability and inversely correlate with infiltrated mature dendritic cells . Atherosclerosis 2013 ; 230 : 92 – 99 . Google Scholar Crossref Search ADS PubMed WorldCat 36 Jonasson L , Holm J, Skalli O, Gabbiani G, Hansson GK. Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis . J Clin Invest 1985 ; 76 : 125 – 131 . Google Scholar Crossref Search ADS PubMed WorldCat 37 Jonasson L , Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque . Arteriosclerosis 1986 ; 6 : 131 – 138 . Google Scholar Crossref Search ADS PubMed WorldCat 38 Hansson GK , Hermansson A. The immune system in atherosclerosis . Nat Immunol 2011 ; 12 : 204 – 212 . Google Scholar Crossref Search ADS PubMed WorldCat 39 Arbab-Zadeh A , Nakano M, Virmani R, Fuster V. Acute coronary events . Circulation 2012 ; 125 : 1147 – 1156 . Google Scholar Crossref Search ADS PubMed WorldCat 40 Virmani R , Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions . Arterioscler Thromb Vasc Biol 2000 ; 20 : 1262 – 1275 . Google Scholar Crossref Search ADS PubMed WorldCat 41 De Palma R , Del Galdo F, Abbate G et al. Patients with acute coronary syndrome show oligoclonal T-cell recruitment within unstable plaque: evidence for a local, intracoronary immunologic mechanism . Circulation 2006 ; 113 : 640 – 646 . Google Scholar Crossref Search ADS PubMed WorldCat 42 Caligiuri G , Paulsson G, Nicoletti A, Maseri A, Hansson GK. Evidence for antigen-driven T-cell response in unstable angina . Circulation 2000 ; 102 : 1114 – 1119 . Google Scholar Crossref Search ADS PubMed WorldCat 43 Liuzzo G , Goronzy JJ, Yang H et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes . Circulation 2000 ; 101 : 2883 – 2888 . Google Scholar Crossref Search ADS PubMed WorldCat 44 Canducci F , Saita D, Foglieni C et al. Cross-reacting antibacterial auto-antibodies are produced within coronary atherosclerotic plaques of acute coronary syndrome patients . PLOS ONE 2012 ; 7 : e42283 . Google Scholar Crossref Search ADS PubMed WorldCat 45 Stemme S , Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein . Proc Natl Acad Sci USA 1995 ; 92 : 3893 – 3897 . Google Scholar Crossref Search ADS PubMed WorldCat 46 Pessi T , Karhunen V, Karjalainen PP et al. Bacterial signatures in thrombus aspirates of patients with myocardial infarction . Circulation 2013 ; 127 : 1219 – 1228 . Google Scholar Crossref Search ADS PubMed WorldCat 47 Ammirati E , Cianflone D, Vecchio V et al. Effector memory T cells are associated with atherosclerosis in humans and animal models . J Am Heart Assoc 2012 ; 1 : 27 – 41 . Google Scholar Crossref Search ADS PubMed WorldCat 48 Mach F , Sauty A, Iarossi AS et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells . J Clin Invest 1999 ; 104 : 1041 – 1050 . Google Scholar Crossref Search ADS PubMed WorldCat 49 van Loosdregt J , van Oosterhout MF, Bruggink AH et al. The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response . Circulation 2006 ; 114 : 1599 – 1607 . Google Scholar Crossref Search ADS PubMed WorldCat 50 van Wanrooij EJ , de Jager SC, van Es T et al. CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice . Arterioscler Thromb Vasc Biol 2008 ; 28 : 251 – 257 . Google Scholar Crossref Search ADS PubMed WorldCat 51 Braunersreuther V , Steffens S, Arnaud C et al. A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice . Arterioscler Thromb Vasc Biol 2008 ; 28 : 1090 – 1096 . Google Scholar Crossref Search ADS PubMed WorldCat 52 Frostegard J , Ulfgren AK, Nyberg P et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines . Atherosclerosis 1999 ; 145 : 33 – 43 . Google Scholar Crossref Search ADS PubMed WorldCat 53 Erbel C , Dengler TJ, Wangler S et al. Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability . Basic Res Cardiol 2011 ; 106 : 125 – 134 . Google Scholar Crossref Search ADS PubMed WorldCat 54 de Boer OJ , van der Meer JJ, Teeling P, van der Loos CM, van der Wal AC. Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions . PLOS ONE 2007 ; 2 : e779 . Google Scholar Crossref Search ADS PubMed WorldCat 55 Patel S , Chung SH, White G, Bao S, Celermajer DS. The ‘atheroprotective’ mediators apolipoprotein A-I and Foxp3 are over-abundant in unstable carotid plaques . Int J Cardiol 2010 ; 145 : 183 – 187 . Google Scholar Crossref Search ADS PubMed WorldCat 56 Klingenberg R , Brokopp CE, Grives A et al. Clonal restriction and predominance of regulatory T cells in coronary thrombi of patients with acute coronary syndromes . Eur Heart J 2014 ; [Epub ahead of print]. Google Scholar OpenURL Placeholder Text WorldCat 57 Bobryshev YV , Lord RS. Identification of natural killer cells in human atherosclerotic plaque . Atherosclerosis 2005 ; 180 : 423 – 427 . Google Scholar Crossref Search ADS PubMed WorldCat 58 Methe H , Brunner S, Wiegand D, Nabauer M, Koglin J, Edelman ER. Enhanced T-helper-1 lymphocyte activation patterns in acute coronary syndromes . J Am Coll Cardiol 2005 ; 45 : 1939 – 1945 . Google Scholar Crossref Search ADS PubMed WorldCat 59 Engelbertsen D , Andersson L, Ljungcrantz I et al. T-helper 2 immunity is associated with reduced risk of myocardial infarction and stroke . Arterioscler Thromb Vasc Biol 2013 ; 33 : 637 – 644 . Google Scholar Crossref Search ADS PubMed WorldCat 60 Ammirati E , Cannistraci CV, Cristell NA et al. Identification and predictive value of interleukin-6+ interleukin-10+ and interleukin-6- interleukin-10+ cytokine patterns in ST-elevation acute myocardial infarction . Circ Res 2012 ; 111 : 1336 – 1348 . Google Scholar Crossref Search ADS PubMed WorldCat 61 Neri Serneri GG , Prisco D, Martini F et al. Acute T-cell activation is detectable in unstable angina . Circulation 1997 ; 95 : 1806 – 1812 . Google Scholar Crossref Search ADS PubMed WorldCat 62 Liuzzo G , Kopecky SL, Frye RL et al. Perturbation of the T-cell repertoire in patients with unstable angina . Circulation 1999 ; 100 : 2135 – 2139 . Google Scholar Crossref Search ADS PubMed WorldCat 63 Teo FH , de Oliveira RT, Mamoni RL et al. Characterization of CD4+CD28null T cells in patients with coronary artery disease and individuals with risk factors for atherosclerosis . Cell Immunol 2013 ; 281 : 11 – 19 . Google Scholar Crossref Search ADS PubMed WorldCat 64 Ammirati E , Vermi AC, Cianflone D et al. Expansion of T-cell receptor zeta dim effector T cells in acute coronary syndromes . Arterioscler Thromb Vasc Biol 2008 ; 28 : 2305 – 2311 . Google Scholar Crossref Search ADS PubMed WorldCat 65 Cheng X , Yu X, Ding YJ et al. The Th17/Treg imbalance in patients with acute coronary syndrome . Clin Immunol 2008 ; 127 : 89 – 97 . Google Scholar Crossref Search ADS PubMed WorldCat 66 Zhao Z , Wu Y, Cheng M et al. Activation of Th17/Th1 and Th1, but not Th17, is associated with the acute cardiac event in patients with acute coronary syndrome . Atherosclerosis 2011 ; 217 : 518 – 524 . Google Scholar Crossref Search ADS PubMed WorldCat 67 Liuzzo G , Biasucci LM, Trotta G et al. Unusual CD4+CD28null T lymphocytes and recurrence of acute coronary events . J Am Coll Cardiol 2007 ; 50 : 1450 – 1458 . Google Scholar Crossref Search ADS PubMed WorldCat 68 Han SF , Liu P, Zhang W et al. The opposite-direction modulation of CD4+CD25+ Tregs and T helper 1 cells in acute coronary syndromes . Clin Immunol 2007 ; 124 : 90 – 97 . Google Scholar Crossref Search ADS PubMed WorldCat 69 Mor A , Luboshits G, Planer D, Keren G, George J. Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes . Eur Heart J 2006 ; 27 : 2530 – 2537 . Google Scholar Crossref Search ADS PubMed WorldCat 70 Ammirati E , Cianflone D, Banfi M et al. Circulating CD4+CD25hiCD127lo regulatory T-Cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis . Arterioscler Thromb Vasc Biol 2010 ; 30 : 1832 – 1841 . Google Scholar Crossref Search ADS PubMed WorldCat 71 Olson NC , Doyle MF, Jenny NS et al. Decreased naive and increased memory CD4(+) T cells are associated with subclinical atherosclerosis: the multi-ethnic study of atherosclerosis . PLOS ONE 2013 ; 8 : e71498 . Google Scholar Crossref Search ADS PubMed WorldCat 72 Tanigawa T , Kitamura A, Yamagishi K et al. Relationships of differential leukocyte and lymphocyte subpopulations with carotid atherosclerosis in elderly men . J Clin Immunol 2003 ; 23 : 469 – 476 . Google Scholar Crossref Search ADS PubMed WorldCat 73 Ait-Oufella H , Taleb S, Mallat Z, Tedgui A. Recent advances on the role of cytokines in atherosclerosis . Arterioscler Thromb Vasc Biol 2011 ; 31 : 969 – 979 . Google Scholar Crossref Search ADS PubMed WorldCat 74 Paul WE , Seder RA. Lymphocyte responses and cytokines . Cell 1994 ; 76 : 241 – 251 . Google Scholar Crossref Search ADS PubMed WorldCat 75 Libby P , Lichtman AH, Hansson GK. Immune effector mechanisms implicated in atherosclerosis: from mice to humans . Immunity 2013 ; 38 : 1092 – 1104 . Google Scholar Crossref Search ADS PubMed WorldCat 76 Butterworth AS , Braund PS, Farrall M et al. Large-scale gene-centric analysis identifies novel variants for coronary artery disease . PLOS Genet 2011 ; 7 : e1002260 . Google Scholar PubMed OpenURL Placeholder Text WorldCat 77 Sampi M , Ukkola O, Paivansalo M, Kesaniemi YA, Binder CJ, Horkko S. Plasma interleukin-5 levels are related to antibodies binding to oxidized low-density lipoprotein and to decreased subclinical atherosclerosis . J Am Coll Cardiol 2008 ; 52 : 1370 – 1378 . Google Scholar Crossref Search ADS PubMed WorldCat 78 Taleb S , Romain M, Ramkhelawon B et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis . J Exp Med 2009 ; 206 : 2067 – 2077 . Google Scholar Crossref Search ADS PubMed WorldCat 79 Eid RE , Rao DA, Zhou J et al. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells . Circulation 2009 ; 119 : 1424 – 1432 . Google Scholar Crossref Search ADS PubMed WorldCat 80 Liuzzo G , Giubilato G, Pinnelli M. T cells and cytokines in atherogenesis . Lupus 2005 ; 14 : 732 – 735 . Google Scholar Crossref Search ADS PubMed WorldCat 81 Dumitriu IE , Baruah P, Finlayson CJ et al. High levels of costimulatory receptors OX40 and 4-1BB characterize CD4+CD28null T cells in patients with acute coronary syndrome . Circ Res 2012 ; 110 : 857 – 869 . Google Scholar Crossref Search ADS PubMed WorldCat 82 Sakaguchi S , Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance . Cell 2008 ; 133 : 775 – 787 . Google Scholar Crossref Search ADS PubMed WorldCat 83 de Boer OJ , van der Wal AC. FOXP3+ regulatory T cells in vulnerable atherosclerotic plaques . Int J Cardiol 2010 ; 145 : 161 . Google Scholar Crossref Search ADS PubMed WorldCat 84 Lichtman AH , Binder CJ, Tsimikas S, Witztum JL. Adaptive immunity in atherogenesis: new insights and therapeutic approaches . J Clin Invest 2013 ; 123 : 27 – 36 . Google Scholar Crossref Search ADS PubMed WorldCat 85 Vivier E , Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells . Nat Immunol 2008 ; 9 : 503 – 510 . Google Scholar Crossref Search ADS PubMed WorldCat 86 Melian A , Geng YJ, Sukhova GK, Libby P, Porcelli SA. CD1 expression in human atherosclerosis. A potential mechanism for T cell activation by foam cells . Am J Pathol 1999 ; 155 : 775 – 786 . Google Scholar Crossref Search ADS PubMed WorldCat 87 Tomura M , Honda T, Tanizaki H et al. Activated regulatory T cells are the major T cell type emigrating from the skin during a cutaneous immune response in mice . J Clin Invest 2010 ; 120 : 883 – 893 . Google Scholar Crossref Search ADS PubMed WorldCat 88 Backteman K , Andersson C, Dahlin LG, Ernerudh J, Jonasson L. Lymphocyte subpopulations in lymph nodes and peripheral blood: a comparison between patients with stable angina and acute coronary syndrome . PLOS ONE 2012 ; 7 : e32691 . Google Scholar Crossref Search ADS PubMed WorldCat 89 Ridker PM . Hyperlipidemia as an instigator of inflammation: inaugurating new approaches to vascular prevention . J Am Heart Assoc 2012 ; 1 : 3 – 5 . Google Scholar Crossref Search ADS PubMed WorldCat 90 Sallusto F , Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions . Nature 1999 ; 401 : 708 – 712 . Google Scholar Crossref Search ADS PubMed WorldCat 91 Ammirati E , Monaco C, Norata GD. Antigen-dependent and antigen-independent pathways modulate CD4+CD28null T-cells during atherosclerosis . Circ Res 2012 ; 111 : e48 – 49 . author reply e50–1. Google Scholar PubMed OpenURL Placeholder Text WorldCat 92 Baniyash M . TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response . Nat Rev Immunol 2004 ; 4 : 675 – 687 . Google Scholar Crossref Search ADS PubMed WorldCat 93 Zhang X , Niessner A, Nakajima T et al. Interleukin 12 induces T-cell recruitment into the atherosclerotic plaque . Circ Res 2006 ; 98 : 524 – 531 . Google Scholar Crossref Search ADS PubMed WorldCat 94 Zhang Z , Gorman CL, Vermi AC et al. TCRzetadim lymphocytes define populations of circulating effector cells that migrate to inflamed tissues . Blood 2007 ; 109 : 4328 – 4335 . Google Scholar Crossref Search ADS PubMed WorldCat 95 Hansson GK , Libby P. The immune response in atherosclerosis: a double-edged sword . Nat Rev Immunol 2006 ; 6 : 508 – 519 . Google Scholar Crossref Search ADS PubMed WorldCat 96 Wysocki CA , Jiang Q, Panoskaltsis-Mortari A et al. Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease . Blood 2005 ; 106 : 3300 – 3307 . Google Scholar Crossref Search ADS PubMed WorldCat 97 Klingenberg R , Gerdes N, Badeau RM et al. Depletion of FOXP3+ regulatory T cells promotes hypercholesterolemia and atherosclerosis . J Clin Invest 2013 ; 123 : 1323 – 1334 . Google Scholar Crossref Search ADS PubMed WorldCat 98 Caligiuri G , Nicoletti A, Poirier B, Hansson GK. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice . J Clin Invest 2002 ; 109 : 745 – 753 . Google Scholar Crossref Search ADS PubMed WorldCat 99 Huan T , Zhang B, Wang Z et al. A systems biology framework identifies molecular underpinnings of coronary heart disease . Arterioscler Thromb Vasc Biol 2013 ; 33 : 1427 – 1434 . Google Scholar Crossref Search ADS PubMed WorldCat 100 Houtkamp MA , de Boer OJ, van der Loos CM, van der Wal AC, Becker AE. Adventitial infiltrates associated with advanced atherosclerotic plaques: structural organization suggests generation of local humoral immune responses . J Pathol 2001 ; 193 : 263 – 269 . Google Scholar Crossref Search ADS PubMed WorldCat 101 Burioni R , Canducci F, Saita D et al. Antigen-driven evolution of B lymphocytes in coronary atherosclerotic plaques . J Immunol 2009 ; 183 : 2537 – 2544 . Google Scholar Crossref Search ADS PubMed WorldCat 102 Ma CS , Deenick EK, Batten M, Tangye SG. The origins, function, and regulation of T follicular helper cells . J Exp Med 2012 ; 209 : 1241 – 1253 . Google Scholar Crossref Search ADS PubMed WorldCat 103 Martin F , Kearney JF. B1 cells: similarities and differences with other B cell subsets . Curr Opin Immunol 2001 ; 13 : 195 – 201 . Google Scholar Crossref Search ADS PubMed WorldCat 104 Goncalves I , Gronholdt ML, Soderberg I et al. Humoral immune response against defined oxidized low-density lipoprotein antigens reflects structure and disease activity of carotid plaques . Arterioscler Thromb Vasc Biol 2005 ; 25 : 1250 – 1255 . Google Scholar Crossref Search ADS PubMed WorldCat 105 Kyaw T , Tay C, Hosseini H et al. Depletion of B2 but not B1a B cells in BAFF receptor-deficient ApoE mice attenuates atherosclerosis by potently ameliorating arterial inflammation . PLOS ONE 2012 ; 7 : e29371 . Google Scholar Crossref Search ADS PubMed WorldCat 106 Kovanen PT , Manttari M, Palosuo T, Manninen V, Aho K. Prediction of myocardial infarction in dyslipidemic men by elevated levels of immunoglobulin classes A, E, and G, but not M . Arch Intern Med 1998 ; 158 : 1434 – 1439 . Google Scholar Crossref Search ADS PubMed WorldCat 107 Howitt MR , Garrett WS. A complex microworld in the gut: gut microbiota and cardiovascular disease connectivity . Nat Med 2012 ; 18 : 1188 – 1189 . Google Scholar Crossref Search ADS PubMed WorldCat 108 Tang WH , Wang Z, Levison BS et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk . N Engl J Med 2013 ; 368 : 1575 – 1584 . Google Scholar Crossref Search ADS PubMed WorldCat 109 Karvonen J , Paivansalo M, Kesaniemi YA, Horkko S. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis . Circulation 2003 ; 108 : 2107 – 2112 . Google Scholar Crossref Search ADS PubMed WorldCat 110 Gigante B , Leander K, Vikstrom M et al. Low levels of IgM antibodies against phosphorylcholine are associated with fast carotid intima media thickness progression and cardiovascular risk in men . Atherosclerosis 2014 ; 236 : 394 – 399 . Google Scholar Crossref Search ADS PubMed WorldCat 111 Tsimikas S , Willeit P, Willeit J et al. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events . J Am Coll Cardiol 2012 ; 60 : 2218 – 2229 . Google Scholar Crossref Search ADS PubMed WorldCat 112 Tsiantoulas D , Diehl CJ, Witztum JL, Binder CJ. B cells and humoral immunity in atherosclerosis . Circ Res 2014 ; 114 : 1743 – 1756 . Google Scholar Crossref Search ADS PubMed WorldCat 113 McLeod O , Silveira A, Fredrikson GN et al. Plasma autoantibodies against apolipoprotein B-100 peptide 210 in subclinical atherosclerosis . Atherosclerosis 2014 ; 232 : 242 – 248 . Google Scholar Crossref Search ADS PubMed WorldCat 114 Tsimikas S , Brilakis ES, Lennon RJ et al. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events . J Lipid Res 2007 ; 48 : 425 – 433 . Google Scholar Crossref Search ADS PubMed WorldCat 115 Wang J , Cheng X, Xiang MX et al. IgE stimulates human and mouse arterial cell apoptosis and cytokine expression and promotes atherogenesis in Apoe−/− mice . J Clin Invest 2011 ; 121 : 3564 – 3577 . Google Scholar Crossref Search ADS PubMed WorldCat 116 Muscari A , Bozzoli C, Gerratana C et al. Association of serum IgA and C4 with severe atherosclerosis . Atherosclerosis 1988 ; 74 : 179 – 186 . Google Scholar Crossref Search ADS PubMed WorldCat 117 Yla-Herttuala S , Bentzon JF, Daemen M et al. Stabilisation of atherosclerotic plaques. Position paper of the European Society of Cardiology (ESC) Working Group on atherosclerosis and vascular biology . Thromb Haemost 2011 ; 106 : 1 – 19 . Google Scholar PubMed OpenURL Placeholder Text WorldCat 118 Kovacic JC , Gupta R, Lee AC et al. STAT3-dependent acute RANTES production in vascular smooth muscle cells modulates inflammation following arterial injury in mice . J Clin Invest 2010 ; 120 : 303 – 314 . Google Scholar Crossref Search ADS PubMed WorldCat 119 Massberg S , Brand K, Gruner S et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation . J Exp Med 2002 ; 196 : 887 – 896 . Google Scholar Crossref Search ADS PubMed WorldCat 120 Gori AM , Cesari F, Marcucci R et al. The balance between pro- and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients . Atherosclerosis 2009 ; 202 : 255 – 262 . Google Scholar Crossref Search ADS PubMed WorldCat 121 Todoroki N , Watanabe Y, Akaike T et al. Enhancement by IL-1 beta and IFN-gamma of platelet activation: adhesion to leukocytes via GMP-140/PADGEM protein (CD62) . Biochem Biophys Res Commun 1991 ; 179 : 756 – 761 . Google Scholar Crossref Search ADS PubMed WorldCat 122 Oleksowicz L , Paciucci PA, Zuckerman D, Colorito A, Rand JH, Holland JF. Alterations of platelet function induced by interleukin-2 . J Immunother 1991 ; 10 : 363 – 370 . Google Scholar Crossref Search ADS PubMed WorldCat 123 Stafford NP , Pink AE, White AE, Glenn JR, Heptinstall S. Mechanisms involved in adenosine triphosphate-induced platelet aggregation in whole blood . Arterioscler Thromb Vasc Biol 2003 ; 23 : 1928 – 1933 . Google Scholar Crossref Search ADS PubMed WorldCat 124 Li N , Ji Q, Hjemdahl P. Platelet–lymphocyte conjugation differs between lymphocyte subpopulations . J Thromb Haemost 2006 ; 4 : 874 – 881 . Google Scholar Crossref Search ADS PubMed WorldCat 125 Diacovo TG , Roth SJ, Morita CT, Rosat JP, Brenner MB, Springer TA. Interactions of human alpha/beta and gamma/delta T lymphocyte subsets in shear flow with E-selectin and P-selectin . J Exp Med 1996 ; 183 : 1193 – 1203 . Google Scholar Crossref Search ADS PubMed WorldCat 126 Hu H , Zhu L, Huang Z et al. Platelets enhance lymphocyte adhesion and infiltration into arterial thrombus . Thromb Haemost 2010 ; 104 : 1184 – 1192 . Google Scholar Crossref Search ADS PubMed WorldCat 127 Elzey BD , Tian J, Jensen RJ et al. Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments . Immunity 2003 ; 19 : 9 – 19 . Google Scholar Crossref Search ADS PubMed WorldCat 128 Gerdes N , Zhu L, Ersoy M et al. Platelets regulate CD4(+) T-cell differentiation via multiple chemokines in humans . Thromb Haemost 2011 ; 106 : 353 – 362 . Google Scholar PubMed OpenURL Placeholder Text WorldCat 129 Skaggs BJ , Hahn BH, McMahon M. Accelerated atherosclerosis in patients with SLE – mechanisms and management . Nat Rev Rheumatol 2012 ; 8 : 214 – 223 . Google Scholar Crossref Search ADS PubMed WorldCat 130 Frostegard J . Atherosclerosis and cardiovascular disease in rheumatoid arthritis . J Rheumatol 2012 ; 39 : 2233 – 2234 . Google Scholar Crossref Search ADS PubMed WorldCat 131 Ammirati E , Bozzolo EP, Contri R et al. Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus . Nutr Metab Cardiovasc Dis 2014 ; 24 : 751 – 759 . Google Scholar Crossref Search ADS PubMed WorldCat 132 Shoenfeld Y , Gerli R, Doria A et al. Accelerated atherosclerosis in autoimmune rheumatic diseases . Circulation 2005 ; 112 : 3337 – 3347 . Google Scholar Crossref Search ADS PubMed WorldCat 133 Sokolove J , Brennan MJ, Sharpe O et al. Brief report: citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis . Arthritis Rheum 2013 ; 65 : 1719 – 1724 . Google Scholar Crossref Search ADS PubMed WorldCat 134 Hsue PY , Giri K, Erickson S et al. Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection . Circulation 2004 ; 109 : 316 – 319 . Google Scholar Crossref Search ADS PubMed WorldCat 135 Friis-Moller N , Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction . N Engl J Med 2003 ; 349 : 1993 – 2003 . Google Scholar PubMed OpenURL Placeholder Text WorldCat 136 Shrestha S , Irvin MR, Grunfeld C, Arnett DK. HIV, inflammation, and calcium in atherosclerosis . Arterioscler Thromb Vasc Biol 2014 ; 34 : 244 – 250 . Google Scholar Crossref Search ADS PubMed WorldCat 137 Krikke M , van Lelyveld SF, Tesselaar K, Arends JE, Hoepelman IM, Visseren FL. The role of T cells in the development of cardiovascular disease in HIV-infected patients . Atherosclerosis 2014 ; 237 : 92 – 98 . Google Scholar Crossref Search ADS PubMed WorldCat 138 Hansson GK , Nilsson J. Vaccination against atherosclerosis? Induction of atheroprotective immunity . Semin Immunopathol 2009 ; 31 : 95 – 101 . Google Scholar Crossref Search ADS PubMed WorldCat 139 Klingenberg R , Lebens M, Hermansson A et al. Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis . Arterioscler Thromb Vasc Biol 2010 ; 30 : 946 – 952 . Google Scholar Crossref Search ADS PubMed WorldCat 140 Pierides C , Bermudez-Fajardo A, Fredrikson GN, Nilsson J, Oviedo-Orta E. Immune responses elicited by apoB-100-derived peptides in mice . Immunol Res 2013 ; 56 : 96 – 108 . Google Scholar Crossref Search ADS PubMed WorldCat 141 Ridker PM , Thuren T, Zalewski A, Libby P. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) . Am Heart J 2011 ; 162 : 597 – 605 . Google Scholar Crossref Search ADS PubMed WorldCat 142 Ridker PM , Howard CP, Walter V et al. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial . Circulation 2012 ; 126 : 2739 – 2748 . Google Scholar Crossref Search ADS PubMed WorldCat 143 Uchida J , Hamaguchi Y, Oliver JA et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy . J Exp Med 2004 ; 199 : 1659 – 1669 . Google Scholar Crossref Search ADS PubMed WorldCat 144 Bluml S , McKeever K, Ettinger R, Smolen J, Herbst R. B-cell targeted therapeutics in clinical development . Arthritis Res Ther 2013 ; 15 ( Suppl. 1 ): S4 . Google Scholar Crossref Search ADS PubMed WorldCat 145 Ait-Oufella H , Herbin O, Bouaziz JD et al. B cell depletion reduces the development of atherosclerosis in mice . J Exp Med 2010 ; 207 : 1579 – 1587 . Google Scholar Crossref Search ADS PubMed WorldCat 146 Kyaw T , Cui P, Tay C et al. BAFF receptor mAb treatment ameliorates development and progression of atherosclerosis in hyperlipidemic ApoE(–/–) mice . PLOS ONE 2013 ; 8 : e60430 . Google Scholar Crossref Search ADS PubMed WorldCat 147 O'Donoghue ML , Braunwald E, White HD et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial . JAMA 2014 ; 312 : 1006 – 1015 . Google Scholar Crossref Search ADS PubMed WorldCat 148 Mallat Z , Lambeau G, Tedgui A. Lipoprotein-associated and secreted phospholipases A(2) in cardiovascular disease: roles as biological effectors and biomarkers . Circulation 2010 ; 122 : 2183 – 2200 . Google Scholar Crossref Search ADS PubMed WorldCat 149 Ridker PM , Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein . N Engl J Med 2008 ; 359 : 2195 – 2207 . Google Scholar Crossref Search ADS PubMed WorldCat 150 Cristell N , Cianflone D, Durante A et al. High-sensitivity C-reactive protein is within normal levels at the very onset of first ST-segment elevation acute myocardial infarction in 41% of cases: a multiethnic case-control study . J Am Coll Cardiol 2011 ; 58 : 2654 – 2661 . Google Scholar Crossref Search ADS PubMed WorldCat © 2014 British Society for Immunology This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
TI - The role of T and B cells in human atherosclerosis and atherothrombosis
JF - Clinical & Experimental Immunology
DO - 10.1111/cei.12477
DA - 2015-01-02
UR - https://www.deepdyve.com/lp/oxford-university-press/the-role-of-t-and-b-cells-in-human-atherosclerosis-and-kUt2fSj07S
SP - 173
EP - 187
VL - 179
IS - 2
DP - DeepDyve
ER -